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FOREWORD
This dissertation has resulted to three publications. 
Chapters III and IV which discuss the comparison of fruc­
tose 6-phosphate-l-kinase (PFK) from Bacillus stearother- 
mophilus and from E. coli, and the mutation at the fruc­
tose 6-phosphate binding site have been combined into one 
paper. This has been accepted for publication in the 
Journal of Biological Chemistry and is entitled "Site- 
directed Mutagenesis in Bacillus stearothermophilus Fruc­
tose 6-phosphate-l-kinase: Mutation at the Substrate Bind­
ing Site Affects Allosteric Behavior" co-authored by B. C. 
Valdez, B. A. French, E. S. Younathan and S. H. Chang.
The galley proof has been received and returned to the 
publisher. The paper is expected to appear in the journal 
in January, 1989.
Mutation at the regulatory site (Chapter V) has been 
published in Biochemical and Biophysical Research Communi­
cation (Vol. 156, pp. 537-542) and is entitled "Site- 
directed Mutagenesis at the Regulatory Site of Fructose 6- 
phosphate-l-kinase from Bacillus stearothermophilus" co­
authored by B. C. Valdez, S. H. Chang and E. S. Younathan.
The section on human muscle PFK gene (Chapter VI) has 
been accepted for publication in Gene and is entitled 
"Human 6-phosphofructo-l-kinase Gene Has an Additional 
Intron Upstream of Initiation Codon". This is co-authored
iii
by B. C. Valdez, Z. Chen, M. G. Sosa, E. S. Younathan and 
S. H. Chang. The revised manuscript has been submitted.
iv
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ABSTRACT
Fructose 6-phosphate-l-kinase (PFK: EC. 2.7.1.11) 
catalyzes the phosphorylation of g-fructose 6-phosphate 
(Fru 6-P) to 6-fructose 1,6-bisphosphate. The first part 
of this dissertation shows that PFK from Bacillus 
stearothermophilus (BsPFK) unlike the major PFK from E . 
coli (EcPFKA) exhibits a hyperbolic profile with respect 
to Fru 6-P concentration in the absence of 
phosphoenolpyruvate (PEP). BsPFK is sensitive to 
inhibition by high ATP concentrations and competitively 
inhibited by GDP or ADP.
Arg-252 residue of BsPFK has been proposed to be 
involved in the binding of Fru 6-P. Mutation of this 
residue to alanine (RA252) increases BsPFK affinity for 
its inhibitor PEP (a 68-fold difference compared to wild 
type) and dramatically decreases Fru 6-P affinity (1,500- 
fold increase in Km). Its higher sensitivity to ATP 
inhibition is relieved by ADP, GDP or higher Fru 6-P 
concentrations. Mutation of Arg-252 to lysine (RK252) 
increases the affinity of the enzyme for PEP by only 2- 
fold and increases its Km for Fru 6-P by only 50-fold.
The data indicate that the Arg-252 residue plays a major 
role in both Fru 6-P binding and allosteric interaction 
between the subunits.
Arg-25, Arg-211 and Asp-59 residues have been mutated 
to alanine; and Asp-59 also to methionine. Arg-25 mutant
X
has half the affinity for Fru 6-P compared to the wild 
type and exhibits sigmoidicity with respect to this 
substrate (Hill # = 2.0). Asp-59 Ala mutant has the 
same affinity for PEP as the wild type whereas Asp 59 
Met mutant has 3-fold higher affinity for this modulator 
and the inhibition is reversed by GDP. Arg-25 and Arg-211 
mutants are 100-fold less sensitive to PEP inhibition 
which is not relieved by GDP. The data prove 
unequivocally that Arg-25 and Arg-211, but not Asp-59, are 
involved in the direct binding of PEP and GDP.
The last part of this dissertation involves isolation 
of a clone containing the nontranslated 5' flanking region 
of the human muscle PFK (HMPFK) gene. It has an 
additional intron extending from nucleotide -97 to -9 
upstream of the ATG start codon. Furthermore, HMPFK gene 
is more AT rich than the rabbit gene.
CHAPTER I 
INTRODUCTION
Background
Phosphofructokinase (PFK) (ATP: g-D-fructose 6- 
phosphate-l-phosphotransferase, E.C. 2.7.1.11) catalyzes 
the transfer of the terminal phosphate from ATP to the C- 
hydroxyl of g-D-fructose 6-phosphate (Fru 6-P) to produce 
g-D-fructose 1,6-bisphosphate and ADP as shown below.
Fru 6-P2- + MgATP4" *s=r Fru 1,6-P.,4' + MgADP3- + H+
This is the first committed step in glycolysis; hence it 
is not surprising that this enzyme is subject to strong 
regulation by various metabolites. The extent of 
regulation of this enzyme depends on its source. In 
general, bacterial PFKs are regulated by a smaller number 
of modulators compared to PFKs from higher organisms. 
Comprehensive reviews on PFK have been reported in the 
literature (Bloxham and Lardy, 1973; Uyeda, 1979; 
Younathan et_al., 1981).
Studies on the mechanism of action and the structure 
function relationships of PFK are made possible by the 
isolation of this enzyme in pure form from various 
sources. Most of the conclusions made are based on the 
interpretation of kinetic data. With the advances in 
recombinant DNA technology the methodology to study these
relationships has become more sophisticated. The first 
part of this dissertation specifically involves studying 
the structure-function relationships in PFK from Bacillus 
stearothermophilus (BsPFK) by site-directed mutation.
Expression of eucaryotic genes is more complicated 
than procaryotic genes. A number of transcription factors 
and cis-acting sequences are involved in eucaryotic gene 
expression (Wingender, 1988). The second part of this 
dissertation involves cloning and sequencing the upstream 
region of the human muscle fructose 6-phosphate-l-kinase 
(HMPFK) gene. This is an initial step to characterize the 
promoter region of this gene and to identify any cis- 
acting sequences probably involved in HMPFK gene 
expression.
Reaction Mechanism of PFK
Phosphofructokinases differ in terms of kinetics of 
their regulation. This probably explains the various 
reaction mechanisms of substrate-binding and product- 
release reported in the literature for this enzyme. Both 
bi-bi sequential random and ping-pong mechanisms were 
proposed for rabbit muscle PFK (Hanson et al., 1973;
Uyeda, 1970; Kee and Griffin, 1972; Bar-tana and Cleland, 
1974). An ordered sequencial mechanism was reported for 
heart and liver PFKs (Hulme and Tipton, 1971; Brand and 
Soling, 1974).
Studies on the reaction mechanism of procaryotic PFKs 
are very limited. Non-allosteric PFK from Lactobacillus 
plantarum has been found to follow an ordered bi-bi 
sequential mechanism where fructose 6-phosphate binds to 
the enzyme first and ADP is the first product to be 
released (Simon and Hofer, 1978). The minor non- 
allosteric PFK from E. coli (EcPFKB) follows the same 
sequence of kinetic mechanism (Campos et al., 1984) 
whereas the major allosteric PFK from E. coli (EcPFKA) 
follows an opposite order of mechanism (i.e. ATP binds 
first and Fru 1,6-P2 is the first product released)
(Kotlarz and Buc, 1981). The determination of the order 
of binding of substrates and release of products are based 
on kinetic data. This, however, does not provide 
information about the exact bioorganic mechanism of 
phosphoryl transfer. Lowe et al. (1981) have used
isotopically labeled ATP to show the inversion of 
configuration in the phosphoryl transfer catalyzed by PFK 
from B. stearothermophilus and rabbit muscle. This 
implies an "in line" transfer of the phosphoryl group 
between substrates in the Fru 6-P - Mg-ATP - enzyme 
ternary complex. Site-directed mutation has recently been 
used to demonstrate that the same mechanism of phosphoryl 
transfer holds true for EcPFKA (Hellinga and Evans, 1987). 
In general, PFKs probably differ on the order of substrate 
binding and release of products but they follow the same
bioorganic mechanism of phosphoryl transfer.
Regulation of PFK Activity
Procaryotic PFKs are half the molecular size _of 
eucaryotic PFKs but their properties may be as diverse as 
the mammalian enzyme. Their allosteric behavior depends 
on their sources and the requirement for metabolic 
control. Studies on the major E. coli PFK show sigmoidal 
dependence of enzyme activity on the concentrations of the 
substrate Fru 6-P (Atkinson and Walton, 1965; Blangy et 
al., 1968). Similar kinetic profile has been reported for 
Lactobacillus acidophilus (Simon and Hofer, 1977), 
Streptococcus lactis (Fordyce et al., 1982), Thermus X-l 
(Cass and Steelwagen, 1975) and B. stearothermophilus 
(Evans et al., 1981). However, Valdez et al. (1988) show
that B. stearothermophilus exhibits a hyperbolic kinetic 
profile with respect to Fru 6-P concentration similar to 
PFKs from Lactobacillus plantarum (Simon and Hofer, 1977), 
Streptococcus thermophilus (Simon and Hofer, 1981), 
Bacillus licheniformis (Marschke and Bernlohr, 1982), 
Flavobacterium thermophilus (Yoshida, 1978) and the minor 
PFK from E. coli (Babul, 1978; Kotlarz and Buc, 1981).
At low Fru 6-P concentrations, ATP has been observed 
to inhibit some bacterial PFKs (Simon and Hofer, 1977; 
Fordyce et al., 1982; Marschke and Bernlohr, 1982; Babul, 
1978; Kotlarz and Buc, 1981). Phosphoenolpyruvate is a
common inhibitor among procaryotic PFKs. The enzyme 
isolated from L. acidophilus (Simon and Hofer, 1977) and 
the minor E. coli PFK (Babul, 1978) are examples of 
procaryotic PFKs insensitive to phosphoenolpyruvate. In 
general, an increase in the ADP concentration in bacterial 
cells activates PFK, increasing the rate of glycolysis to 
produce more ATP. Accumulation of phosphoenolpyruvate 
inhibits PFK in a feedback mechanism.
A thorough kinetic study made by Blangy et al. (1968)
on EcPFKA shows that the properties of the enzyme may be 
explained by the concerted transition theory proposed by 
Monod et al. (1965). The enzyme belongs to the K-system
where the R (relaxed) conformation has a higher binding 
affinity for Fru 6-P and ADP than the T (tight) 
conformation but both states have the same maximal 
velocity.
PFKs from higher organisms are affected by numerous 
metabolites. This is explained by the vital role 
glycolysis plays in carbohydrate metabolism. This 
regulation is made more complicated by the presence of 
three PFK isozymes in animals (M-type, L-type and C-type 
for muscle, liver and brain respectively). In general, 
eucaryotic PFKs are inhibited allosterically by high ATP 
concentrations and it decreases the affinity for the 
second substrate, Fru 6-P (Lardy and Parks, 1956; Hofmann, 
1976; Uyeda, 1979). This inhibition is relieved by the
degradation products of ATP (AMP, ADP and Pi) (Passonneau 
and Lowry, 1963; Tornheim and Lowenstein, 1976). The 
dependence of PFK activity on the ratio between ATP and 
ADP or AMP concentration implies the importance of 
regulation of this enzyme by the energy charge of a cell.
The link between glycolysis and TCA cycle is shown by 
the inhibition of PFK by citrate in the presence of 
inhibitory concentrations of ATP (Garland et al., 1963; 
Passonneau and Lowry, 1963; Tsai and Kemp, 1974) . Muscle 
PFK is more sensitive to the inhibition when compared to 
the brain or liver enzyme (Tsai and Kemp, 1974) which 
implies isozyme differences in the sensitivity to citrate 
inhibition.
Other effective inhibitors of eucaryotic PFKs are 
phosphocreatine, 3-phosphoglycerate, 2-phosphoglycerate,
2,3-bisphosphoglycerate, 6-phosphogluconate and 
phosphoenolpyruvate (Bloxham and Lardy, 1973; Uyeda,
1979) .
The inhibition of eucaryotic PFKs may be relieved by 
AMP, cAMP, ADP, Pi, Fru 6-P and Fru 1,6-P2 (Uyeda, 1979). 
Other positive effectors include ammonium ion (Abrahams 
and Younathan, 1971), Fru 2,6-P2 (Claus et al., 1981; 
Kelley et al., 1986) Glu 1,6-P2 (Krzanowski and 
Matshinsky, 1969), and Man 1,6-P2 (Rose and Warms, 1974).
Most eucaryotic PFKs exhibit cooperative Fru 6-P 
binding. Negative effectors shift the Fru 6-P saturation
curve to more sigmoidal form (decreases the apparent 
affinity of Fru 6-P) while its positive effectors change 
the curve to hyperbolic form (increases the affinity of 
Fru 6-P).
It is interesting to consider, at this point, the 
anomeric specificity of phosphofructokinase. Younathan et 
al. (1981) have shown that rabbit muscle PFK is specific 
for the 6-enantiomeric form of Fru 6-P. On the other 
hand, fructose 1,6-bisphosphatase, an important enzyme in 
gluconeogenesis shows a preference for a-Fru 1,6-P2 
(Benkovic et al., 1974). This shows the difference in the 
specificity of the two enzymes involved in the Fru 6-P:
Fru 1,6-P2 futile cycle.
The physiological activities of some mammalian PFK's 
are under hormonal regulation. Insulin causes an increase 
in liver and muscle PFK activity while glucagon has an 
opposite effect (Taunton et al., 1972; Taunton et al., 
1974; Bauer and Younathan, 1984). Early studies show that 
the hormones probably affect the direct phosphorylation of 
PFK (Nakatsu and Mansour, 1974; Brand and Soling, 1975). 
However, the discovery of Fru 2,6-P2 gives a breakthrough 
in the understanding of this stringent control. Fru 2,6- 
P2 is a potent activator of PFK and the level of this 
metabolite is determined by the balance of flux of 6- 
phosphofructo-2-kinase (PFK-2) and Fru 2,6-bisphosphatase 
(FBPase-2), both located on the same polypeptide chain
(El-Magharabi et al., 1982: Tauler et al., 1988). 
Phosphorylation of this bi-functional enzyme by cAMP- 
dependent protein kinase activates the FBPase-2 and 
inhibits the PFK-2 activities (Pilkis et al., 1987).
In addition to this post-translational regulation, 
insulin probably enhances gene expression of the liver 
isozyme. Gehnrich et al. (1988) have shown that the level 
of mouse liver PFK mRNA is under hormonal, dietary and 
developmental control which is similar to what has been 
observed for other hepatic glycolytic enzymes.
Immunological Cross-reactivity of PFKs
Immunological study is a technique that provides 
structural and evolutionary relationships among proteins. 
Immunological cross-reactivity among different enzymes 
suggests the existence of similarity in their amino acid 
sequence and spatial arrangement of the peptide chain. 
Antigenic determinants are usually located on the surface 
of a protein molecule; hence antibodies are sensitive 
probes for structural homologies within this part of a 
protein (Margoliash et al., 1970; Proger and Wilson,
1971) .
Kotlarz and Buc (1982) reported the immunological 
relationships between the two PFKs from E. coli K12 and 
other bacteria. The major E. coli PFK showed strong 
cross-reactivity with PFKs from B. stearothermophilus,
Shigella boydii. Shigella sonnei, Salmonella typhimurium.
Klebsiella pneumoniae and Klebsiella oxytocans. They 
concluded that the major E. coli PFK has strong structural 
and functional similarities with PFKs from these 
organisms. Antibody raised against PFK from L. plantarum 
cross-reacted with PFKs from B. stearothermophilus. 
Streptococcus thermophilus, L. acidophilus, and 
Lactobacillus helveticus but not with E. coli PFKs (Simon 
and Hofer, 1981). The close immunologic relationship of 
PFKs from B. stearothermophilus and other bacteria implies 
the existence of homology in their structures.
Studies on immunological cross-reactivity of 
eucaryotic PFKs are not as thorough as those on the 
procaryotic enzyme. Rabbit muscle PFK antibody has a very 
low reactivity with the rabbit erythrocyte enzyme (Tarui 
et al., 1972). Cross-reactivity has not been observed 
among the three rat PFK isozymes (Dunaway and Kasten,
1987), or among the three human PFK isozymes (Dunaway and 
Kasten, 1988). They have used antibodies to quantify the 
amount of PFK subunits in each tissue.
Immunological cross-reactivity may be considered as 
an initial step in the structural homology studies among 
PFKs from various sources. The penultimate technique to 
comprehend the relationship between structure and 
properties of proteins is the determination of their 
primary and crystallographic structures which may be
proven unequivocally and ultimately by site-directed 
mutations.
Structure of PFK
PFK is active in its tetrameric form. Each subunit 
has a molecular mass of 34,000-87,000 depending on its 
source. The entire amino acid sequence of BsPFK has been 
established (Kolb et al., 1980; French and Chang, 1987). 
Comparison of its amino acid sequence with PFK from rabbit 
muscle and E. coli shows that the eucaryotic PFK has 
evolved probably by duplication of the bacterial gene 
(Poorman et al., 1984) .
The crystallographic structure of the active form of 
BsPFK has been determined to 2.4 A resolution (Evans and 
Hudson, 1979). Three ligand binding sites have been 
located. The Fru 6-P binding site and effector site 
(where phosphoenolpyruvate, ADP and GDP bind) are in 
between two subunits whereas ATP binding site resides 
within one subunit. The roles of amino acid residues in 
these sites have been described in detail and compared 
with homologous PFKs from E. coli and rabbit muscle (Evans 
et al., 1981; Hellinga and Evans, 1985) (Table 1). Some 
of these putative amino acid residues have been mutated in 
the homologous E. coli PFK. Mutation of Glu-187 to Ala in 
the effector site makes PEP an activator rather than an 
inhibitor (Lau and Fersht, 1987) and truncation of Tyr-55
11
Table 1. A comparison of residues in the ligand-binding 
sites of three related PFK's: EcPFKA (EC), BsPFK (BS) , and 
the N-terminal and C-terminal halves of RMPFK [RM(N) and 
RM(C)]. Residues are listed under their number in the 
BsPFK sequence. Residues contributing to sites A and C 
are divided between neighboring subunits in the tetramer. 
Residues marked * are not in the subunit containing the 
main part of the site. The dyad symmetry axis relating 
the subunit containing these residues to that containing 
the main site are given as (p), (q) or (r). (Adapted from
Hellinga and Evans, 1985.)
A. Site A F m l f iP  binding
Residue Residue type
number EC BS RM(N) RM(C) Comments
125 Thr Thr Ser T hr H bond to  1-phosphate
127 Asp Asp Asp Ser Catalytic residue, H bond to 0 (31
129 Asp Asp Asp Asn Binds w ater attached to  Mg3 +
162*(r) Arg Arg Arg Arg Binds 6-phosphate
169 Met Met Met Met Hydrophobic contact to 0 (2), 0 <3)
170 Gly Gly Gly Gly Main-chain H bond to  Ol3l
171 Arg Arg Arg Gly Near 1-phosphate
222 Glu Glu Glu Glu H bond to  0 ,4)
243*(r) Arg Arg Arg Arg Binds 6-phosphate
249 His His His His Binds 6-phosphate
252 Arg Arg Arg Gin H bond to  6-phosphate and 0 (2(
B. Site D A DP binding
Residue Residue type
number EC BS RM(N) RM(C) Comments
11 Gly Gly Gly Ala Main-chain amide H bond to /J-P
41 Tyr Tyr Tyr Phe Contact to ribose
72 Arg Arg Arg Arg Bridges ADP a-P and Frul.OP phosphates PI and PC
73 Plie Cys Cys Thr Main-chain amide and carbonyl H bond to rihose OH
77 Arg Lys Arg Lys Hydrophobic contact to adenine
103 Asp Asp Asp (Phe) Binds to Mg3 *
104 Gly Gly Gly (Glu) Main-chain NH H liond to /J-P, no room for side-chain
105 Ser Ser Ser (Leu) H bonds to fl-V from OH and XH
107 Met Gin . Tlir Glu Hydrophobic contact to adenine
108 Gly Gly Gly Gly Contacts adenine
S ite  C  effector site ( A D P )
Residue Residue type
number EC BS RM(N) RM(C) Comments
2 I*(p) Arg Arg Arg Arg H bond to /1-P and to Mg3 t-w ater
25*(p) , Arg Arg Arg Arg H bond to /1-phosphate
54*(I>) Arg Val Trp Trp H bond to a-P  and C terminus
55»(p) Tyr Gly Glu Ser Stacks against adenine ring
58*<P) Ser Gly Ser Gly H bond to a-P  and Arg25
59*(p) Asp Asp Met Gly Main-chain amide H bond to /?-P, side-chain H-bond to ribose 0 |3.,
154 Arg Arg Tlir Lys Two If bonds to /1-P
185 Gly Gly Gly Gly Main-chain carbonyl bonds to Mg3*
187 Glu Glu Asp Asp Carboxyl binds to Mg3*
211 Lys Arg . Thr Lys Alternative to  Arg54
213 Lys Lys Thr Lys H bond to C terminus and <!lulK7
214 Lys Lys Arg Thr Main-chain amide H bond to rihose 0 )4-( (side-chain disordered)
215 His His Gly Thr Bond to Mg3 * via water
C terminus Tyr He — (Val) H bond to Arg54 in K. coti
to Gly proves the presence of an interaction between the 
aromatic ring of the tyrosine residue with guanine of GDP 
(Lau et al., 1987). Site-directed mutations of Arg-21, 
Arg-25, Lys-213, Arg-54, Arg-154 and Asp-59 show that 
these residues are involved in the binding of GDP and PEP 
(Lau and Fersht, 1988). Hellinga and Evans (1987) show 
that Asp-127 is a key residue in the EcPFKA catalysis 
probably acting as a base in the reaction mechanism. Arg- 
162 and Arg-243 have been shown to be important residues 
in the T to R transition of this enzyme (Berger and Evans,
1988) .
The crystallographic structure of allosterically 
inhibited BsPFK has also been determined to 7 i resolution 
(Evans et al., 1986). It may not be as refined as the X- 
ray structure of the active form but it gives a structural 
difference between the two conformations: that is, one 
subunit twists relative to other subunits about 8°. This 
rotation diminishes the access of Fru 6-P to its binding 
site but makes the effector site more accessible to PEP. 
This explains the weak binding of Fru 6-P but strong 
binding of PEP to the T (tight) conformation of the 
enzyme.
The gene encoding BsPFK has been cloned, sequenced 
and expressed to high-level in E. coli (French and Chang, 
1987; French et al., 1987). This provides opportunities 
to study the structure-function relationships in BsPFK and
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to make a comprehensive comparison between this enzyme and 
the major E. coli PFK.
The nucleotide sequence of the rabbit muscle PFK gene 
has been reported (Lee et al., 1987)= The sequence 
identifies additional 30 amino acid residues which are not 
included in the primary structure of PFK published 
earlier (Poorman et al., 1984). More recently, the cDNA 
sequence of human muscle (Nakajima et al., 1987) and mouse 
liver (Gehnrich et al., 1988) PFK have been reported. The 
rabbit muscle PFK gene has higher nucleotide homology with 
the human muscle PFK gene than the mouse liver gene.
Site-directed Mutagenesis and Protein Engineering
The rapid advances in the technology of 
oligonucleotide synthesis have led to wide applications of 
synthetic oligonucleotides in molecular biology. One of 
the powerful techniques that use this tool is site- 
directed mutagenesis. It involves annealing a mutagenic 
oligonucleotide primer to a single-stranded DNA template, 
extending the primer by DNA polymerization, ligating the 
ends, and transfecting competent bacterial cells.
The methodologies and applications of site-directed 
mutagenesis have been reviewed in the literature (Smith,
1985; Bolstein and Shortle, 1985; Carter, 1986;
Leatherbarrow and Fersht, 1986). The approaches for 
oligonucleotide-directed mutation have a common strategy:
creation of an asymmetry between two DNA strands to 
increase the frequency of mutation. Some of these 
asymmetries employ the use of hemimethylated DNA (Kramer 
et al., 1982; Marmenout et al., 1984), nonsense codons 
(Kramer et al., 1984; Carter et al., 1985), restriction 
modification systems in E. coli (Carter et al., 1985; 
Carter, 1987), y-phosphorothionate dNTP analogue (Taylor 
et al., 1985a; Taylor et al., 1985b) and uracil residues 
in place of thymine (Kunkel, 1985; Kunkel et al., 1987).
In this dissertation, the use of uracil residues in 
place of thymine is employed. Briefly, a single stranded 
uracil-containing M13 DNA template is produced within a 
dut" ung“ mutant strain of E. coli. This strain lacks 
dUTPase and uracil N-glycosylase activities; hence uracil 
is incorporated into but not removed from the DNA. The 
mutagenic synthetic oligonucleotide primer is annealed 
into the uracil-containing template prior to in vitro 
synthesis of the second normal strand. Transfection of 
the heteroduplex strands into wild-type dut+ ung+ strain 
results in excision of the uracil residues and production 
of pyrimidinic (AP) sites thereby preferentially enriching 
the strand that carries the mutation.
Early reports on the use of oligonucleotide-directed 
mutagenesis to study protein function were on tyrosyl-tRNA 
synthetase (Winter et al., 1982), 8-lactamase (Dalbaldie- 
McFarland et al., 1982; Sigal et al., 1982; Charles et
al., 1982) and prolipoprotein (Inouye et al., 1982).
Since then the number of proteins modified by this 
technique had increased tremendously.
The most common application of mutagenesis in protein 
chemistry is the study of the contribution of individual 
amino acid residue to enzyme catalysis and regulation. It
is possible to elucidate the mechanism of enzyme catalysis
in a way that no other method allows (Straus et al., 1985; 
Fersht et al., 1986). Mutagenesis may also be used to 
localize specific functional zones (Waye et al., 1983; 
Bedouelle and Winter, 1986) and to alter physical 
properties of a protein (such as thermal stability, pH 
optimum, molecular size and subunit composition) (Wells 
and Powers, 1986; Robey and Schachman, 1985). It is,
therefore, possible to produce enzymes with novel
properties by protein engineering using oligonucleotide- 
directed mutagenesis.
Rationale and Objectives
The properties of a protein are dictated by its 
structure. Proteins of related function have been shown 
to have common structural features. NAD-dependent 
dehydrogenases, for example, have been shown to have a 
common domain of six parallel 8-sheet strands in a 6-a-6 
structure (Levitt and Clothia, 1976). Some DNA binding 
proteins have Zn-finger or leucine-zipper structures which
are believed to be essential for nucleic acid binding 
(Klug and Rhodes, 1987; Landschulz et al., 1988). The 
importance of these structures can be proven unequivocally 
by mutations of certain key amino acid residues involved 
in their polypeptide chains.
Phosphofructokinase is one of the enzymes the 
properties of which have been thoroughly studied.
However, there are still questions on the relationship 
between its function and structure. BsPFK is a good 
system to study and answer some of these questions. The 
BsPFK molecule is smaller compared to other PFKs; hence it 
is easier to correlate experimental data with its 
structure. Its thermal stability makes this enzyme easier 
to handle. The availability of its crystallographic 
structure provides good structural information including 
precise locations of amino acid residues involved in 
ligand binding. BsPFK cross-reacts with antibodies raised 
against various PFKs more than any other procaryotic PFKs. 
Therefore, structural study on this enzyme may provide 
important information on the structure of other 
procaryotic PFKs.
Crystallographic studies on BsPFK have shown that 
Arg-252 plays a critical role in subunit assembly and 
orientation. It forms hydrogen bonds with both the 
substrate of the enzyme, Fru 6-P, and with the adjacent 
subunit to stabilize the quaternary structure of the
active tetramer (Evans et al., 1981). X-ray 
crystallograph of allosterically inhibited BsPFK reveals 
subunit twisting to limit access to the Fru 6-P binding 
site (Evans et al., 1986). Mutation of Arg-252 may lower 
Fru 6-P binding and may weaken subunit interaction. In 
this study, Arg-252 has been mutated to Ala and to Lys to 
determine how the length and charge of side chain affects 
the magnitude of changes in the properties of the enzyme.
ADP, GDP and PEP bind to the same regulatory site in 
BsPFK. The amino acid residues involved in the binding of 
these modulators have been identified from the X-ray 
structure of the enzyme (Evans et al., 1981). Among these 
residues are Arg-25, Arg-211 and Asp-59. Each has been 
mutated to Ala to prove that the three residues are 
involved in the binding of the activator(s) and inhibitor. 
In the homologous rabbit muscle PFK, Asp-59 is replaced by 
Met; hence a Met-59 mutant BsPFK has also been 
constructed.
The study of transcriptional control in eucaryotic 
PFK is of equal importance as the structure-function 
relationship in the procaryotic enzyme. Mammalian PFK has 
three types of subunits which associate to form 
homotetramer or heterotetramer depending on the abundance 
of the subunits in a particular tissue. These PFK 
isozymes exhibit different allosteric behavior, thus they 
respond to tissue-specific regulation of glycolysis
(Dunaway and Kasten, 1987). Understanding the tissue- 
specific expression of their genes requires knowledge of 
the nucleotide sequence of the different PFK isozyme 
genes, especially their promoter regions. The isolation 
of the 5' flanking region of human muscle PFK gene will 
help in the study of the cis-regulatory sequence and any 
trans-acting factor that might regulate this gene. This 
will also give an insight into its expression in patients 
with glycogen storage disease type VII (Vora et al.,
1983).
This study has been conducted with the following 
specific aims:
1. To compare kinetic properties of authentic BsPFK, 
cloned BsPFK and cloned EcPFKA;
2. To establish conditions for site-directed mutation 
in BsPFK and express mutants to high-level;
3. To determine how subunit interaction is affected 
by mutation of Arg-252 (located at the Fru 6-P binding 
site) to lysine or alanine;
4. To correlate experimental results on Arg-252 
mutations with R to T transformation;
5. To mutate Arg-25, Arg-211 and Asp-59 (located at 
the allosteric site) and determine their role in the 
binding of GDP and PEP; and
6. To clone, sequence and characterize the 5' non­
translated region of the human muscle PFK gene.
CHAPTER II 
MATERIALS AND METHODS
Materials
A. Enzymes
Restriction endonucleases were purchased from 
Bethesda Research Laboratories (BRL) (Bethesda, MD), New 
England Biolabs, Inc. (NEB) (Beverly, MA), Boehringer- 
Mannheim Biochemicals (Indianapolis, IN) and Pharmacia 
(Piscataway, NJ). T4 DNA ligase and DNA polymerase I 
(Klenow Fragment) were obtained from BRL and NEB. 
Sequenase kit was ordered from United States Biochemicals 
Corp. (Cleveland, OH). RNAse A, aldolase (Type IV), 
mixture of triose-phosphate isomerase and glycerol 3- 
phosphate dehydrogenase (Type III) and creatine 
phosphokinase were purchased from Sigma Chemical Co. (St. 
Louis, MO).
B. Chemicals
Bacto-tryptone, bacto-yeast extract, and bacto-agar 
were purchased from Difco Laboratory (Detroit, MI). 
Agarose, dithiothreitol, urea and phenol were obtained 
from BRL. Acrylamide, N',N-methylene-bisacrylamide, 
TEMED, and ammonium persulfate were ordered through BIO­
RAD (Richmond, CA). Low melting point SeaPlaque agarose 
was purchased from FMC Corporation (Rockland, ME). 
Methanol, ethanol, chloroform and acetic acid were
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purchased from Fisher Scientific (Fair Lawn, NJ) and 
American Scientific Products (McGaw Park, IL).
Tris(hydroxymethyl)aminomethane (Tris), 
ethylenediaminetetraacetic acid (EDTA), magnesium 
chloride, ammonium chloride, nicotinamide adenine 
dinucleotide (reduced form, NADH), sodium chloride, sodium 
hydroxide, phenylmethylsulfonyl fluoride, Cibacron Blue 
3GA-Agarose (Type 3000-CL-L), fructose 6-phosphate (sodium 
salt), adenosine triphosphate (sodium salt), adenosine 
diphosphate (sodium salt), guanosine triphosphate (sodium 
salt), guanosine diphosphate (sodium salt), 
phosphoenolpyruvate, creatine phosphate,
polyethyleneglycol (PEG 6000), ampicillin and bovine serum 
albumin were obtained from Sigma Chemical Co. 
Nitrocellulose filters were purchased from Schleicher and 
Schuell (Keene, NH). Prepared Sephadex G-50 (Select D) 
columns were obtained from 5 Prime - 3 Prime, Inc. (West 
Chester, PA) and NACS PREPAC columns from BRL.
Polyethylene imine cellulose F plates were purchased from 
EM Science (West Germany). 3MM Whatman filter papers were 
ordered from Fisher Scientific. ATP-agarose (Type II) was 
obtained from Pharmacia. Films (XAR-5 and XRP-5) were 
purchased from Eastman Kodak Co. (Rochester, NY).
C. Radionucleotides and oligonucleotides
[a-32P]-dATP was purchased from ICN Biochemicals,
Inc. (Cleveland, OH). [Y-32P]-ATP and [a-35s ]thio-dATP 
were obtained from New England Nuclear, Inc. (Boston, MA) 
Oligonucleotides were synthesized by solid support 
phosphite chemistry (Matteucci and Caruthers, 1981) in an 
automated DNA synthesizer (Applied Biosystems Model 380A)
D. DNA and Bacterial Strains
M13mpl8, Ml3mpl9 and pBR322 were obtained from BRL. 
M13Bspfk was constructed by French and Chang (1987). 
mHElOll, an M13mp8 clone containing the major E. coli PFK 
gene (EcpfkA) (Hellinga and Evans, 1985), was a gift from 
Dr. P. Evans (MRC, Cambridge, UK). E. coli strains DH5 
and DH5 F' competent cells were purchased from BRL. E. 
coli strain DF1020 [a recA derivative of DF1010 (Daldal, 
1983): pro-82, pfkB201, recA56, (rha-pfkA)200, endAl, 
hsdR17, supE44, thi-11 was kindly provided by Dr. Barbara 
Bachmann of the E. coli Genetic Stock Center (Yale 
University School of Medicine, New Haven, CN). Bacillus 
stearothermophilus NCA 1503 (ATCC 7 954) was obtained from 
the American Type Culture Collection (Rockville, MD).
Common Solutions/Reagents
LB (Luria-Bertani) Medium:
Per liter:
Bacto-tryptone 10 g
Bacto-yeast extract 5 g
NaCl 10 g
Adjust pH to 7.5.
YT Medium:
Per liter:
Bacto-tryptone 10 g
Bacto-yeast extract 10 g
NaCl 5 g
Adjust pH to 7.5.
Sonication Buffer:
50 mM Tris-Cl (pH 7.4)
1 mM DTT 
0.1 mM EDTA
0.1 mM phenylmethylsulfonyl fluoride (PMSF) 
(0.1 M PMSF is prepared in ethanol.)
Low-salt Sonication Buffer:
Sonication buffer containing 0.25 M NaCl
High-salt Sonication Buffer:
Sonication buffer containing 1.5 M NaCl.
Lysozyme Solution:
50 mM glucose 
10 mM EDTA
25 mM Tris-Cl (pH 8.0)
4 mg/ml lysozyme
Add powdered lysozyme to the solution just before 
use.
Tris-EDTA (TE):
10 mM Tris-Cl (pH 8.0) 
1 mM EDTA
Tris-Acetate (TAE):
Per liter 50X stock solution:
Tris base 242 g
glacial acetic acid 57.1 ml
0.5 M EDTA (pH 8.0) 100 ml
Tris-Borate (TBE):
Per liter 5X stock solution:
Tris base 54 g
Boric acid 27.5 g
0.05 M EDTA (pH 8.0) 20 ml
Agarose Gel-loading Buffer:
10X stock solution:
0.25 % Bromophenol blue 
0.25 % Xylene cyanol FF
25 % Ficoll (Type 400) in water
Store at room temperature.
SSC:
20X stock solution:
NaCl 175.3 g
Sodium citrate 88.2 g
H,0 800 ml
Adjust pH to 7.0 and complete the volume to 1 liter. 
Sterilize by autoclaving.
Denhardt's Solution:
50X stock solution:
Ficoll 5 g
Polyvinylpyrrolidone 5 g
BSA 5 g
H20 to 500 ml
Filter through 0.45-um membrane and store at -20°C.
Medium-salt Digestion Buffer: 
10X stock solution:
100 mM Tris-Cl (pH 7.5) 
500 mM NaCl 
100 mM MgCl2 
10 mM DTT
Subcloning and Expression of BsPFK
BsPFK gene was subcloned from M13Bspfk (French and 
Chang, 1987) to pBR322 and expressed to high level in E. 
coli as described by French et al. (1987) .
A. Rapid Preparation of DNA
M13Bspfk RF DNA was prepared similar to the alkaline 
lysis method described by Maniatis et al. (1982). An
overnight culture of JM107 was diluted 50-fold with 2X YT 
medium. Four ml of this suspension was infected with 0.5 
ul M13Bspfk phage and incubated for 5 1/2 hours at 37°C on 
a roller shaker. The cells were harvested by spinning for 
10 min using a microcentrifuge tube. Using a drawn-out 
pipet the supernatant was sucked with vacuum. It was re­
spun for 30 seconds and any liquid was removed. Each 
pellet from the original 1.5 ml cell culture was suspended 
in 100 ul freshly prepared ice-cold lysozyme solution and 
was vortexed for 2 min. It was stored at room temperature 
for 5 min and 200 ul of 0.2 N NaOH/1% SDS solution was 
added. Cell lysis was facilitated by inverting the tube 
three or four times and was held on ice for 5 min.
Proteins were precipitated by adding 150 ul chilled 
potassium acetate solution (pH 4.8), prepared by mixing
6.0 ml of 5 M potassium acetate, 1.15 ml acetic acid and 
2.85 ml H20. The tube was inverted three to four times 
and stored on ice for 5 min. The denatured proteins were 
separated by spinning for 5 min and 0.40 ml supernatant 
was carefully transferred to a fresh tube avoiding the 
white precipitate. Unprecipitated proteins were extracted 
at room temperature by adding 0.40 ml of phenol/CHCl3 
mixture (1:1) by vortexing for 2 min, spinning for 3 min 
and transferring the top aqueous phase to a fresh tube 
avoiding the interface. This was further extracted with 
0.4 ml CHC13 by vortexing 'for 2 min, spinning for 3 min
and transferring the aqueous phase to a fresh tube. The 
DNA was precipitated with 0.8 ml ethanol for 2 min at room 
temperature. It was spun for 2 min and the supernatant 
was aspirated completely. The pellet was further cleaned 
by dissolving in 100 ul of 0.3 M sodium acetate (pH 5.2) 
and adding 250 ul ethanol. After 2 min at room 
temperature the DNA was pelleted by spinning for 2 min and 
the supernatant was removed completely. One ml of 70 % 
ethanol (room temperature) was added, vortexed for 1 min, 
spun for 1 min and the supernatant was removed. The DNA 
pellet was vacuum dried for 5 min and dissolved in 50 ul 
of TE buffer containing DNAse-free RNAse A (10 ug/ml).
B. Digestion of DNA
Thirty ul of M13Bspfk RF DNA (from rapid preparation) 
was digested with 20 units Hindlll in a medium-salt buffer 
containing 0.1 ug/ul BSA for 2 hrs at 37°C. The final 
volume was 80 ul. This was heated at 80-85°C for 5 min to 
denature Hindlll. After cooling to room temperature, the 
NaCl concentration was adjusted to 100 mM and 20 units 
EcoRI were added. Incubation at 37°C was continued for 
another two hours. pBR322 (10 ug) to be used as a vector 
was digested with Hindlll and EcoRI following the same 
procedure.
Both digests were run on a 1 % low melting point 
SeaPlaque agarose (FMC Biochemicals) in IX TEA buffer at
75 volts until the fast moving dye reached the bottom of 
the gel. DNA bands were visualized with ethidium bromide 
(0.5 ug/ml) in TAE buffer.
The 2.5 kb Bspfk and the pBR322 bands were cut out of
the gel and were purified using NACS PREPAC column
following the procedure recommended by the supplier. 
Briefly, the gel slice was placed in an Eppendorf tube and 
melted at 70°C water bath. Four volumes of 0.625 M NaCl 
in TE buffer was added and the diluted gel mix was 
incubated at 70°C for 10 min. This was transferred to a 
40°C water bath for 10 min and loaded at once onto a 
PREPAC column previously equilibrated with 0.5 M NaCl in 
TE buffer. The bound DNA was washed with the same buffer
(5 ml) and was eluted with 0.1 ml of 2 M NaCl in TE
buffer, three times. The effluents were pooled and 10 ug 
tRNA plus 0.6 ml of cold (-20°C) 95 % ethanol were added. 
The samples were cooled down to -70°C for 10 min and 
centrifuged for 15 min. The pellet was washed carefully 
with 80 % ethanol (-20°C) , vacuum dried for 5 min, and 
resuspended in 20 ul TE buffer.
C . Ligation
The following is an example of a ligation reaction: 
BRL 5X ligation buffer (4 ul), H20 (5 ul), purified 
Hindlll/EcoRI digested pBR322 (5 ul), purified Bspfk 
fragment (5 ul), and BRL 1 U/ul ligase (1 ul). This was
incubated overnight at 15°C.
D. Transformation of DH5a Cells
E. coli DH5a competent cells were used in the 
transformation following the protocol provided by the 
supplier (BRL) (Appendix 1). Ten representative 
transformants were picked up with sterile tooth picks and 
each was used to inoculate 4 ml LB medium containing 50 
ug/ml ampicillin. The plasmid was isolated following the 
previously described procedure for RF DNA preparation. To 
check for size of the insert, the recombinant plasmid DNA 
was digested with Hindlll and EcoRI as described before.
E. Transformation of DF1020 Cells
DF1020, a pfk-negative E. coli strain, was prepared 
according to the FSB method of Hanahan (1983) (Appendix 
2). This was transformed with pBR322/Bspfk similar to the 
transformation of DH5 cells. One ul of 10-fold diluted 
pBR322/Bspfk DNA was used to transform 30 ul DF1020 
competent cells. Ten representative recombinants were 
checked for size of insert as described above.
Purification of Cloned BsPFK
A. Growing of Cells and Sonication
A colony of transformed DF1020 was used to inoculate 
5 ml 2X YT broth containing 100 ug/ml ampicillin. This
was incubated overnight at 37°C on a roller shaker. A 
portion of the overnight culture (1.5 ml) was mixed with 
500 ml 2X YT medium containing 100 ug/ml ampicillin. This 
was incubated at 37°C on a rotary shaker (250 rpm). After 
14 hrs of incubation, a 1.5 ml sample aliquot was obtained 
to assay for PFK activity. Briefly, the cells in the 
aliquot was spun down using an Eppendorf centrifuge. This 
was resuspended in 0.5 ml sonication buffer and sonicated 
on ice for 1 min using Sonicator Ultrasonic Cell Disruptor 
Model W-225R (Heat Systems-Ultrasonics, Inc., Farmingdale, 
NY) with the following settings: pulse, level 6, 50 %, 
microtip. The cell extract was centrifuged at 4°C for 5 
min and the supernatant was assayed for PFK activity as 
described below. This sampling for PFK activity was 
repeated every 2 hrs until the activity reached at least 
10 U/ml of crude extract.
Cells were then pelleted by centrifugation at 4°C,
5,000 Xg for 10 min using Sorvall Centrifuge RC2-B. (The 
cells can be stored at -20°C without appreciable loss in 
activity.) The cells were weighed and resuspended at 10 % 
in sonication buffer. The cell suspension in plastic 
centrifuge tube was sonicated (pulse, 50 %, level 6, horn 
tip) at 0°C for 1 min. This was repeated 5 times with 1
min cooling interval. The crude lysate was centrifuged
for 1 hr at 12,000 Xg, 4°C. The supernatant was saved and
the residue was resuspended in 10 ml sonication buffer.
This second cell suspension was sonicated as described 
above 3 times, centrifuged and the supernatants were 
pooled together.
B . Heat Treatment
The clear supernatant solution was heated at 70°C for 
15 min, cooled on ice, and centrifuged for 1 hr at 12,000 
Xg, 4°C. Longer heating was sometimes used but a prior 
small scale heat treatment was done. Sample of 0.5 ml was 
put in an Eppendorf tube, heated at 70°C water bath, and 
aliquoted 0.1 ml for PFK assay after 15, 30, 45, and 60 
min.
The heated sample was adjusted to 0.25 M NaCl by 
adding appropriate amount of 5 M NaCl (2.7 ml of 5 M NaCl 
per 50 ml sample). The concentrated NaCl solution was 
added drop by drop while stirring the sample gently at 4°C 
to prevent protein denaturation.
C . Column Chromatography
Cibacron Blue 3GA-Agarose (12 g) was suspended in 
sonication buffer and gently stirred at 4°C to break any 
clumps for at least 1 hr. The resin was transferred into 
a BIO-RAD yellow column (30 X 1.5 cm) without trapping air 
bubbles. The resin was equilibrated at 4°C with low-salt 
sonication buffer using a peristaltic pump at the rate of 
0.35 ml/min. This was usually done overnight. The
conductivities of the equilibration buffer and the eluate 
were compared to determine if the resin was equilibrated. 
The sample was loaded onto the column maintaining the same 
flow-rate of 0.35 ml/min. The column was washed with low- 
salt sonication buffer until the absorbance of the eluate 
at 280 nm was almost zero.
A linear salt gradient was used to elute BsPFK. The 
inner cylinder of BRL gradient former was filled with 85 
ml low-salt sonication buffer and the outer chamber was 
filled with equal volume of high-salt sonication buffer. 
While stirring the inner chamber, the buffer was pumped 
into the column. Each fraction collected was about 2.8 
ml. The absorbance of each fraction was measured at 280 
nm. PFK activity was determined using the standard assay 
condition described below. The purity of all active 
fractions was determined using a 12.5 % SDS-PAGE (Appendix 
7) .
D. Glycerol Concentration
Fractions containing pure BsPFK were pooled and 
transferred to a clean dialysis tube (3/4 inch diameter). 
This was dialyzed against 50 % glycerol in sonication 
buffer in 1 liter graduated cylinder stirred at 4°C.
After 4 hrs, the orange clamp that sealed the dialysis 
tube was adjusted to the reduced volume of the active 
fraction. This was transferred to a 2-liter sonication
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buffer and stirred at 4°C to remove NaCl and glycerol.
After 4 hrs, the tube was dialyzed again against 50 % 
glycerol. This cycle of concentration and removal of 
glycerol was repeated until the volume of PFK solution was 
reduced to 1.5 - 2 ml. The last dialysis step was against 
50 % glycerol so that the sample may be stored at -20°C.
Purification of Authentic BsPFK
Native or authentic BsPFK was isolated from B. 
stearothermophilus strain NCA 1503. A colony was used to 
inoculate 25 ml of LB medium and was incubated at 57°C 
overnight by using a rotary shaker at 25 rpm. This was 
scaled up by seeding 500 ml LB with 5 ml of overnight 
culture and incubating at 57°C until the optical density 
at 700 nm reached 0.8 (late log phase) to prevent 
sporulation. The authentic BsPFK was purified in the same 
way as the cloned BsPFK except using a different resin in 
the column chromatography.
Agarose coupled to N6-(6-aminohexyl)-adenosine 5'- 
triphosphate (ATP-Agarose) was obtained as a suspension.
About 10 ml was transferred in a BIO-RAD column (20X1 cm) 
and equilibrated with low-salt sonication buffer as 
described by Kolb et al. (1980). The sample, adjusted to 
0.25 M NaCl, was loaded on the column, washed with the 
same buffer at a flow-rate of 0.35 ml/min. When the 
absorbance of the eluate at 280 nm was almost zero, the
bound enzyme was eluted with 50 uM Fru 6-P in low-salt 
sonication buffer. Fractions which showed PFK activity 
was pooled and concentrated with glycerol as described 
above.
Expression and Purification of EcPFKA
EcPFKA gene in mHElOll was subcloned in the Hindlll 
site of pUC18 similar to the subcloning of Bspfk from 
M13Bspfk to pBR322 as previously described. Expression in 
DF1020 and large scale preparation of the culture and the 
crude extract were similar to that of BsPFK without 
heating the extract.
The crude lysate was further purified using Cibacron 
Blue 3GA-Agarose similar to that of BsPFK except for minor 
modifications. The column was equilibrated with 
sonication buffer, the sample loaded and washed with 
sonication buffer containing 1.5 M NaCl. Finally, EcPFKA 
was eluted using 2 mM ATP/10 mM MgCl2 in sonication 
buffer. Absorbance of the fractions at 280 nm was not 
measured due to the interference of absorbance of ATP. 
However, these were assayed for PFK activity and the 
active fractions were pooled and concentrated using Amicon 
ultrafiltration cell (Amicon Corp., Danver, MA).
Purification and Phosphorylation of Synthetic 
Oligonucleotides
Oligonucleotide in concentrated NH^OH incubated for 
15 hrs at 50°C was evaporated to dryness using SpeedVac 
Concentrator (Sarvant Instruments, Farmingdale, NY). It 
was dissolved in 2.5 ml of 25 mM TEAB and then loaded 
into a SEP-PAK column previously washed with 10 ml of 
CH3CN, 10 ml of 30 % CH3CN in 25 mM TEAB, and 20 ml of 25 
mM TEAB. The bound oligonucleotide was washed with 4 0 ml 
of same buffer or until there was no absorbance at 260 nm. 
This was followed with 5 ml of 10 % CH3CN, 5 ml of 30 % 
CH3CN and 5 ml of 50 % CH3CN (all in 25 mM TEAB) ; the 
washings were saved separately. Each was tested for 
dimethyltrityl group (DMT) by spoting on silica TLC plate 
(Uniplate) (Analtech, Inc., Newark, DE). On top of each 
spot, a drop of 0.1 M p-toluene sulfonic acid in CH3CN was 
added. The plate was heated until the orange color 
appeared. The fraction that gave the brightest orange 
color was dried under vacuum. DMT was removed by 
dissolving it in 1 ml 80 % acetic acid and incubating at 
room temperature for 25 min. The slightly pink solution 
was evaporated to dryness. It was redissolved in 1 ml H20 
and dried again. This was done three times. It was 
dissolved in 200 ul water, quantitatively transferred to a 
siliconized Eppendorf tube and lyophilized. The residue 
was dissolved in 100 ul H20 and 100 ul FDE (80 %
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formamide, 10 mM NaOH, 1 mM EDTA, 0.1 % Bromophenol blue, 
0.1 % Xylene cyanol FF) prior to polyacrylamide gel 
electrophoresis.
Polyacrylamide gel was prepared by adding 15 ul TEMED 
and 80 ul of 50 .% ammonium persulfate to 100 ml gel 
solution (20 % acrylamide, 1 % bisacrylamide, 8 M urea and 
in TBE buffer). It was pre-run at 30 mA for 1 hr. The 
sample was loaded and run at the same condition until the 
fast moving dye reached an inch above the bottom of the 
gel.
The gel was put on top of a fluorescent plate and the 
DNA band was visualized with short wavelength UV lamp.
The band was excised and crushed to a fine powder in a 
polypropylene tube with siliconized glass rod. It was 
suspended in 6 ml of 1 M TEAB and was shaken at 37°C 
overnight. It was filtered on a siliconized sintered 
glass and the filter was washed with 10 ml H20 three 
times. The pooled filtrate was passed through a washed 
SEP-PAK column. The bound DNA was washed with 30 ml of 25 
mM TEAB and eluted with 5 ml of 30 % CH3CN in 25 mM TEAB. 
It was vacuum dried as before, dissolved in 5 ml H20, 
dried again (3X) and the concentration was determined at 
260 nm.
To test the quality of the synthetic oligonucleotide, 
it was end-labeled with 32P. One ug DNA in 70 mM Tris-Cl 
(pH 7.6), 10 mM MgCl2, 5 mM DTT was mixed with [Y-32P]ATP
and T4 polynucleotide kinase (20 units). This was 
incubated at 37°C for 30 min and the incorporation of the 
label was tested by thin layer chromatography 
(polyethylene imine plate and 0.75 M sodium phosphate, pH 
3.5) .
The same procedure was followed for phosphorylation 
of mutagenic synthetic oligonucleotide but unlabled ATP 
was used. The phosphorylated oligonucleotide was purified 
using prepacked Sephadex G-50 from 5 Prime - 3 Prime, Inc. 
The DNA was ethanol precipitated, vacuum dried and 
dissolved in 20 ul of 10 mM Tris-Cl (pH 8.0).
Site-directed Mutagenesis
A. Preparation of Uracil-containing Template
The recombinant M13Bspfk phage was used to prepare 
the uracil-containing single-stranded template for the 
oligonucleotide-directed in vitro mutagenesis as described 
by Kunkel et al. (1987) with minor modifications. The
phage suspension was heated at 60°C for 5 min and spun for 
2 min to kill and remove E. coli cells. This mixture (3 
ul) was added to 30 ml of 2X YT medium inoculated with 1.5 
ml mid-log E. coli BW313 in 250 ml Erlenmeyer flask 
containing 9 ug uridine. This was incubated for 5 1/2 hrs 
at 37°C.
The cells were separated by centrifugation at 5,000 X 
g, 4°C for 10 min. Phage were precipitated from the clear
supernatant by adding 6 ml (one-fifth volume of the 
supernatant) of 20 % PEG 6000/2.5 M NaCl. This was mixed 
well and incubated for 30 min at room temperature. The 
precipitate was collected by spinning at 5,000 Xg for 15 
min at room temperature. The supernatant was poured off 
and the tube was respun. The residual supernatant was 
completely removed and the phage was resuspended in 1.5 ml 
TE buffer, pH 8.0 by vigorous vortexing. The suspension 
was transferred into a polypropylene tube and 1.5 ml 
phenol/CHC13 (1:1) was added. This was vortexed for 2 
min, stored for 5 min at room temperature, vortexed again 
and centrifuged for 5 min using a clinical centrifuge.
The aqueous phase was transferred carefully into a fresh 
tube and equal volume of CHC13 was added. This was 
vortexed for 2 min, spun for 5 min, and the upper layer 
was transferred to a Corex tube. The DNA was precipitated 
by adding 0.1 volume of 3 M sodium acetate (pH 5.2) and 2 
1/2 volumes of ethanol. This was stored at -20°C 
overnight or at -70°C for 30 min prior to spinning at 4°C 
for 20 min. The pellet was washed with 1 ml of 80 % 
ethanol (-20°C) and then dried under vacuum for 5 min. It 
was dissolved in 200 ul TE buffer. The DNA concentration 
was determined at 260 nm using an extinction coefficient 
of 27.8 O.D.-ml/mg-cm (i.e. 1 OD26Q = 36 ug/ml) . The 
purity of the DNA was examined by agarose (0.8 %) gel 
electrophoresis.
B * In vitro DNA Synthesis
To 10 ng of phosphorylated oligonucleotide carrying 
the mutation was added 1 ug of uracil-containing single­
stranded template, 1.8 ul TM buffer (100 mM Tris-Cl, 50 mM 
MgCl2, pH 8.0) and H20 to 15 ul total volume. This was 
incubated at 65°C for 30 min and allowed to anneal at room 
temperature for 10 min.
The following is an example of the synthesis of the 
second strand:
Reagent Volume (ul)
Annealing Mix 10.0
0.1 M HEPES (pH 7.8) buffer 10.0
50 mM DTT 2.4
1 M MgCl, 0.5
25 mM dNTPs mix (A, C, G, T: each
is 25 mM) 1.0
10 mM ATP 5.0
DNA pol I (Klenow) (1 U/ul) 1.5
T4 DNA ligase (1 U/ul) 3.0
H20 16.6
The mixture was put on ice for 5 min, at room temperature
for another 5 min and then at 37°C for 1 1/2 hr. The
reaction was stopped by heating at 80°C for 5 min. The
synthesis was checked by agarose (0.8 %) gel
electrophoresis.
C. Transformation of DH5aF'
The synthesized double-stranded DNA was diluted 5- 
fold, 10-fold, and 50-fold with 10 mM Tris-Cl (pH 8.0).
One ul of the undiluted and diluted DNA was used to 
transform DH5«F' competent cells according to the 
supplier's protocol (Appendix 3).
D. Screening for Mutants
Mutants were identified either by sequencing 
representative recombinants or by screening plaques with 
32P-labeled mutagenic oligonucleotide as hybridization 
probe.
Randomly selected recombinants were picked up from 
the plate. These were sequenced according to the 
procedure described in Appendix 4 but using one reaction 
mix only. The selected reaction mix was one of the 
mutated nucleotides to see the difference between the 
mutant and the wild type (control).
The plaque hybridization screening is described in 
Appendix 5. This is a more tedious procedure but gives 
better chance of identifying the mutant. The selected 
mutant has to be sequenced, too. The primers used for in 
vitro mutation and DNA sequencing are shown in Appendix 6.
DNA Sequencing
Single-stranded template DNA for sequencing was 
prepared similar to the preparation of the template for 
site-directed mutagenesis except for the absence of 
uridine, use of DH5aF' instead of BW313, and half scale. 
Each entire mutated BsPFK gene was sequenced by dideoxy- 
chain termination method (Sanger et al., 1977; Biggin et 
al., 1983) using a Sequenase kit (USBC) to check that no 
other mutations had occured. The procedure and the
primers used for sequencing are in Appendixes 4 and 6, 
respectively.
Assay of PFK Activity
PFK was dialyzed against 1 liter of dialysis buffer 
(50 mM Tris-Cl, 0.5 mM DTT, 0.1 mM EDTA, pH 7.4) for 36 
hrs at 4°C (two changes). The enzyme solution was 
appropriately diluted with 100 mM Tris-Cl/0.1 mM DTT (pH 
8.2 ) prior to enzyme assay. Auxiliary enzymes were mixed 
(112 mg aldolase, 2.4 mg glycerol 3-phosphate 
dehydrogenase, 18 mg triose-phosphate isomerase) and 
dialyzed against 1 liter of 100 mM Tris-Cl (pH 8.2) at 4°C 
for at least 24 hrs (buffer changed twice). Creatine 
phosphokinase solution (1 ug/ul) was always prepared fresh 
in 25 mM Tris-Cl (pH 8.2) . The pH of ATP, ADP and GDP 
solutions were adjusted to 7.0 and the actual 
concentrations were determined spectrophotometrically. 
Phosphoenolpyruvate and creatine phosphate solutions were 
prepared in 25 mM Tris-Cl (pH 8.2).
PFK activity was measured by an assay coupled to NADH 
oxidation (Babul, 1978; Lau et al., 1987). One ml of 
reaction mixture contained 0.1 M Tris-Cl (pH 8.2), 10 mM 
Mgci2, 5 mM NH Cl, 0.2 mM NADH2, 112 ug aldolase, 18 ug 
triose-phosphate isomerase and 2.4 ug glycerol 3-phosphate 
dehydrogenase. The standard assay procedure contained 1 
mM ATP and 1 mM Fru 6-P. To prevent ADP-mediated effects,
ATP was regenerated with 1 mM creatine phosphate and 10 
ug/ml creatine phosphokinase. This regenerating system 
was omitted whenever the effects of ADP or GDP were 
studied. The NADH oxidation was monitored at 340 nm using 
Gilford Response I spectrophotometer at 29°C. By
definition, one unit of activity is the amount of PFK that
catalyzes the conversion of one umole of Fru 6-P to Fru 
1,6-P2 per min.
The following was an example of standard assay 
protocol:
(1) Warm mix good for 100 assays:
Stock solution Volume (ml)
1 M Tris-Cl (pH 8.2) 10.0
1 M MgCl2 1.0
1 M NH^Cl 0.5
20 mM NADH 1.0
H20 81.5
The pH of the warm mix was checked prior to adding the
required volume of deionized water. This was maintained
at 29°C during the assay and 0.94 ml aliquot was used per
assay.
(2) Each assay contained:
Reagent Volume (ul)
0.1 M Fru 6-P 10
0.1 M ATP 10
0.1 M creatine phosphate 10
1 ug/ul creatine phosphokinase 10
Auxiliary enzymes 10
PFK (diluted) 10
Enzymes were always kept on ice except for the diluted PFK
which was more stable at room temperature. Other reagents
were at room temperature during the experiment. The
reaction was initiated by adding PFK solution.
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The effect of pH on BsPFK activity was determined 
using the following buffered solutions: 0.1 M Imidazole-Cl 
(pH 7.0), 0.1 M Tris-Cl (pH 7.4), 0.1 M Tris-Cl (pH 7.8),
0.1 M Tris-Cl (pH 8.2) and 0.1 M Tris-Cl (pH 8.7).
Determination of Kinetic Parameters
Kinetic parameters were calculated using the 
Enzfitter Program by Leatherbarrow (1987) on a personal 
computer. The dissociation constant for PEP was 
calculated according to Blangy et al. (1968) .
Cloning and Sequencing of Human Muscle PFK Gene
Purification of human DNA from liver and construction 
of a genomic library in lambda EMBL4 phage vector followed 
a previously described protocol (Kaiser and Murray, 1985;
Sosa and Cohen, 1988). Phage plaques equivalent to one 
genomic copy (approximately 300,000 plaques) were screened 
for human muscle PFK gene following the described 
procedure (Maniatis et al., 1982). The probes used in 
this screening were nick-translated M13mpl8 RF DNA 
containing rabbit PFK fragments. The purified human 
muscle PFK gene was characterized by its specific 
restriction sites followed by nitrocellulose hybridization 
with nick-translated phage RF DNA containing the 5' region 
of RMPFK gene or an end-labeled oligonucleotide
complementary to codons No. 2 to 8 in the first exon of 
the RMPFK gene as probes. The nitrocellulose filters were 
washed either at a stringency of IX SSC, 68°C using the 
nick-translated probe, or at IX SSC, 60°C using the end- 
labeled probe. The fragments selected from the human PFK 
gene were subcloned in M13mpl8 and M13mpl9 phage vectors. 
DNA sequence analyses were carried out using the 
dideoxynucleotide chain-terminating method (Sanger et al., 
1977) and [ a -35S]thio-dATP (Biggin et al., 1983).
Primers used in these DNA sequence analyses were universal 
M13 primer and oligonucleotdes corresponding or 
complementary to the coding strand of RMPFK gene. To 
obtain more readable bands I used 50 cm buffer gradient 
polyacrylamide sequencing gels (Biggin et al., 1983). The 
top 10 cm was cut away before autoradiography. DNA 
sequence data were processed using the PCS program 
(Lagrimini et al., 1984) on an IBM Personal Computer.
CHAPTER III
COMPARISON OF CLONED BsPFK, AUTHENTIC BsPFK AND EcPFKA
Comparison of the Cloned and the Authentic BsPFK
SDS-PAGE shows that the authentic and the cloned 
BsPFK's have the same molecular weight (Figure 1). Enzyme 
kinetics study proves that they are identical. They 
exhibit the same hyperbolic profiles with respect to Fru 
6-P or ATP concentration (Figures 2 and 3) from pH 7.0 to 
pH 8.7. Highest activity is observed at pH 8.7; however, 
succeeding PFK assays are done at pH 8.2 which is close to 
the physiological value.
Comparison of BsPFK and EcPFKA
Since both the authentic and the cloned BsPFK do not 
show sigmoidal behavior with respect to Fru 6-P, in 
contrast with the data previously reported for BsPFK 
(Evans et al., 1981), cloned BsPFK and cloned EcPFKA are 
compared to settle this discrepancy. In the absence of 
GDP, EcPFKA exhibits sigmoidicity with respect to Fru 6-P 
concentration whereas BsPFK shows a hyperbolic profile 
(Figure 4). Addition of GDP causes EcPFKA to exhibit a 
hyperbolic behavior. BsPFK is not activated by GDP per se 
and it exhibits a sigmoidal curve only in the presence of 
PEP. ATP is a weak inhibitor of BsPFK at low Fru 6-P 
concentrations and this inhibition can be overcome by high 
concentrations of Fru 6-P, GDP or ADP (Figure 5). EcPFKA
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Figure 1. Relative electrophoretic mobilities of BsPFK's. 
Samples of cloned (lane 2) and authentic (lane 3) BsPFK 
were loaded on 12.5 % SDS-PAGE and stained with Coomassie 
Blue. Lane 1: molecular weight (MW) markers; kd, 
kilodaltons
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Figure 2. Dependence of BsPFK activity on Fru 6-P 
concentration at various pH's. Initial velocities were 
measured using 1 mM ATP and the indicated concentrations 
of Fru 6-P for both authentic (A) and cloned (B) BsPFK. 
Assay mixes had pH of 7.0 (□), 7.4 ( + ), 7.8 (O), 8.2
(A) and 8.7 (X ) using the buffers listed under Materials 
and Methods. Relative activities are relative to the 
maximal activity at pH 8.7.
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Figure 3. Dependence of BsPFK activity on ATP 
concentration at various pH's. Initial velocities were 
measured using 1 mM Fru 6-P and the indicated 
concentrations of ATP for both authentic (A) and cloned
(B) BsPFK. Assay mixes had pH of 7.0 (0), 7.4 ( + ), 7.8 
(O), 8.2 (a ) and 8.7 (X) using buffers listed under 
Materials and Methods. Relative activities are relative 
to the maximal activity at pH 8.2.
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Figure 4. Comparison of the effect of Fru 6-P 
concentration on the activity of BsPFK and EcPFKA.
Initial velocities were measured in the absence ( • , 
BsPFK; ▲ , EcPFKA) or in the presence ( o , BsPFK;
A, EcPFKA) of 0.5 mM GDP as described under Materials and 
Methods using 1 mM ATP and the indicated concentations of 
Fru 6-P. Relative activities are based on the maximal 
activity of each enzyme in the absence of GDP for BsPFK 
and in the presence of GDP for EcPFKA.
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Figure 5. Dependence of wild type activity on ATP 
concentration in the absence or presence of an effector at 
two levels of Fru 6-P concentrations. Initial velocities 
were measured using 0.05 mM (A) and 1 mM (B) Fru 6-P and 
other conditions described under Materials and Methods. 
Relative activities were relative to the maximal velocity 
using 1 mM Fru 6-P in the absence of an effector. □ , no 
effector; + , 0.5 mM GDP; O ,0.5 mM PEP; A , 0.5 mM GDP + 
0.5 mM PEP.
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is insensitive to ATP inhibition (Blangy et al., 1968).
Observed difference in the behavior of these two 
purified enzymes are not due to purification differences. 
BsPFK is adjusted to 2 mM ATP and 10 mM MgCl2 and dialyzed 
against the same buffer (0.1 mM Tris-Cl, pH 7.4, 1 mM DTT) 
used for EcPFKA prior to enzyme assay. Moreover, crude 
extracts of the two enzymes exhibit the same behavior as 
the purified ones. The hyperbolic behavior of BsPFK with 
respect to Fru 6-P observed in this study is similar to 
that of the PFK from other thermophilic bacteria, e. g. 
Flavobacterium thermophilum (Yoshida, 1978) and 
Streptococcus thermophilus (Simon and Hofer, 1981), and 
PFK from Bacillus licheniformis (Marschke and Bernlohr, 
1982) and Lactobacillus plantarum (Simon and Hofer, 1977).
BsPFK requires 5 mM NH4+ for maximal activity. K+, 
but not Na+, may be used as a substitute and a much higher 
concentration is required (Figure 6). This requirement 
for NH„+ is similar to EcPFKA and PFK from other sources 
(Abrahams and Younathan, 1971; Simon and Hofer, 1977; 
Fordyce et al., 1982; Marschke and Bernlohr, 1982).
Discussion
Post-translational modification is common in 
eucaryotic proteins but not in procaryotic proteins. This 
is one problem that confronts molecular biologists when 
attempting to clone a gene of a particular enzyme and
Figure 6. Effect of ammonium and potassium ion 
concentration on the activity of BsPFK. (A) Assays were 
conducted as described under Materials and Methods using 1 
mM ATP, 1 mM Fru 6-P and indicated concentration of 
ammonium ion. (B) The effects of potassium and ammonium 
ions on BsPFK activity were compared. Assays were 
conducted using 1 mM ATP, indicated concentration of Fru 
6-P, and varying concentration of potassium and ammonium 
ions. P , 5 mM K+; +, 10 mM K+; O, 5 mM NH+. Relative
activities were relative to maximal velocity using 5 mM 
NH+.
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express it to a high level in a system different from its 
origin. In vivo phosphorylation of PFK from rabbit 
muscle, for example, probably regulates its activity 
(Kitajima et al., 1983). It is, therefore, important to 
always compare the cloned and the authentic enzymes and be 
certain that the two are identical.
The relative mobility in SDS-PAGE and enzyme kinetics 
prove that the cloned and the authentic BsPFK are 
identical. It suggests that there is no post- 
translational modification in BsPFK expression.
The availability of purified cloned BsPFK paves the 
way for a thorough kinetic study of this enzyme. Although 
its crystallographic structure is known (Evans and Hudson, 
1979), its kinetic properties, however, are not as well- 
studied as EcPFKA. Literature on procaryotic PFK 
discusses the kinetic characteristics of EcPFKA while 
using the structural details from BsPFK as a model 
(Fersht, 1985).
An important difference in the behavior of BsPFK and 
EcPFKA is found in this study. BsPFK has been reported 
previously to resemble EcPFKA which exhibits a sigmoidal 
profile with respect fo Fru 6-P, and shows ADP or GDP 
activation and PEP inhibition (Kolb et al., 1980; Evans et 
al., 1981). Results of this study confirm the kinetic 
characteristics of EcPFKA, but reveal that BsPFK exhibits 
significant differences. Specifically, in the absence of
PEP, BsPFK has a hyperbolic kinetic profile with respect 
to Fru 6-P and it is not activated by ADP or GDP.
CHAPTER IV
MUTATION OF ARG-252 TO ALANINE AND TO LYSINE
Mutation, Expression and Purification
A common problem in the Kunkel method (Kunkel, 1985) 
of site-directed mutation is partial deletion of the 
insert during template preparation. This may be due to 
recombination, inherent instability of the insert and/or 
the presence of deoxyuridine in the DNA. Using an M13 
multiplicity of infection of no more than 1 and incubating 
at 37°C for not more than 5.5 hrs apparently eliminates 
the problem of insert deletion (Figure 7) and results in 
an overall 30 % in vitro mutation rate. The mutants are 
selected either by lifting all the plaques with 
nitrocellulose filter or by sequencing randomly selected 
plaques (Figure 8). The plaque hybridization screening 
technique is more laborious but provides higher chance of 
identifying the mutant.
The first amino acid residue that has been mutated in 
this study is Arg-252, a residue that interacts with the 
substrate Fru 6-P and forms hydrogen bonds with the other 
subunit (Figure 9). It has been mutated to lysine and to 
alanine and the nucleotide sequences are shown in Figure 
10.
The in vitro mutation, subcloning and expression of 
BsPFK gene using pBR322 as an expression vector are shown 
in Figures 11 and 12. The 2.5 kb Bspfk fragment contains
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Figure 7. Insert deletion during the preparation of 
uracil containing sincrle-stranded DNA. E. coli BW313 was 
infected with M13Bspfk phage using the indicated 
multiplicity of infection and was incubated at 37°C for 
the specified length of time in the presence of uracil.
The uracil containing single-stranded DNA was purified and 
loaded into 0.8 % agarose gel and visualized under UV 
light by ethidium bromide staining. Lane 1, lambda DNA 
cut with HindiII and EcoRI; lane 2, template DNA obtained 
using an MOI of 1 and incubation of 5 1/2 hours; lane 3 , 
template DNA obtained using an MOI of 3 and incubation 
time of 6 hours.
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Figure 8. Methods of screening for mutants. (A) Track 
sequencing was used to identify DM59 mutant (Asp59 -*■
Met). BsPRl8 (Appendix 6) was used as a primer to do a 
ddT sequencing reaction on wild type (lane 1) and six 
randomly picked plaques (lanes 2-7) and these were loaded 
on a 6 % sequencing gel. The arrow shows the two mutants 
identified (lanes 3 and 4). (B) Plaque hybridization
screening using 32P-labeled Bs211 (Appendix 6) to 
identify RA211 mutant (Arg211 -> Ala) as described under
Materials and Methods. Only the mutant plaques (m in 1) 
hybridized with the probe as shown by the autoradiogram (m 
in 2). Plaques which did not hybridize (w in 1) were 
considered wild type.
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Figure 9. The binding site for Fru 6-P. The residues 
from the two subunits are drawn with solid and open bonds. 
Arg-252 interacts with Fru 6-P and forms a H-bond network 
with the other subunit. (Adapted from Evans et al.,
1981.)
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Figure 10. DNA sequence showing the mutation of Arg-252
to lysine (RK252) and to alanine (RA252) in BsPFK gene. 
In vitro mutation was carried out according to Kunkel's 
protocol (Kunkel, 1985). Sequencing was performed by 
dideoxy chain termination method as described under the 
Materials and Methods. WT: wild type
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Figure 11. Subcloninq and expression of BsPFK gene. The 
2.5 kb Bspfk fragment was subcloned at the EcoRI-Hindlll 
sites of pBR322. The recombinant plasmid was used to 
transform E. coli strain DF1020, a pfk deletion mutant.
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SUBCLONING AND EXPRESSION OF BsPFK 
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Figure 12. In vitro mutagenesis and subcloninq of Bspfk 
mutant into pBR322. (A) Uracil containing single­
stranded DNA (lane 2) was annealed to a mutagenic ' 
synthetic oligonucleotide and the second strand was 
synthesized using T4 DNA polymerase (lane 3). Lane 4, 
purified RF DNA of M13Bspfk. (B) pBR322 (lane 2) and 
M13Bspfk mutant (lane 3) cut with EcoRI and Hindlll. (C) 
Intact pBR322Bspfk (lane 2) and pBR322Bspfk cut with EcoRI 
and Hindlll (lane 3) showing the presence of a 2.5 kb 
fragment containing the BsPFK gene. Lanes Al and Cl, 
lambda DNA cut with EcoRI and Hindlll; lane Bl, lambda DNA 
cut with Hindlll. All gels were 0.8 % agarose and the DNA 
bands were visualized under UV light after ethidium 
bromide staining.
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a promoter recognized by the RNA polymerase in E. coli. 
This allows the BsPFK gene to be expressed to high level 
in an E. coli system.
High level expression of BsPFK in E. coli and the 
thermal stability of this enzyme simplify its 
purification. Heating the extract to 70°C for 15 min 
precipitates other E. coli proteins and inactivates the E. 
coli PFKA thereby preventing any possible endogenous 
contamination if a leak in the mutation of PFK-deficient 
host occurs. The wild type, RK252 and RA252 proteins are 
all stable at 70°C for 15 min. Increased enzyme purity 
can be obtained by longer heating in the presence of Fru 
6-P. Fru 6-P, but not Mg-ATP, renders BsPFK more heat 
stable. A higher ionic strength may be used to elute 
BsPFK from Cibacron Blue 3GA-Agarose whereas EcPFKA can be 
eluted by Mg-ATP from the same column. The use of a PFK- 
def icient host, the thermal lability of EcPFKA and the 
differential binding of host and cloned enzymes to the 
column guarantee the absence of any EcPFKA contamination. 
PFK from Streptococcus lactis (Fordyce et al., 1982) and 
yeast (Bohme et al., 1972) are also eluted from Cibacron 
Blue column at high ionic strength. Table 2 summarizes 
an example of the procedure employed for the purification 
of BsPFK. The purified wild type, RA252 and RK252 enzymes 
are homogeneous as judged by SDS-PAGE (Figure 13) and have 
the same relative electrophoretic mobilities.
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Table 2. Sample purification of BsPFK mutant (DA59). The high 
specific activity of the crude lysate and low purification fold 
imply the high expression of the mutant in the host cell 
DF1020.
Volume
(ml)
Activity
(U/ml)
% Yield [Protein]
(mg/ml)
Specific
Activity
(U/mg)
Fold 
Purif1
Sonication 40.0 218.1 100 6.56 33.2
Heat
Treatment 37.5 161.3 70 2.74 58.9 1.8
Cibacron
Blue 61.5 59.3 42 0.48 123.5 3.7
Glycerol 
Cone'n 2.0 671.4 15 5.28 127.2 3.8
Figure 13. Polyacrylamide gel electrophoresis in the 
presence of dodecvl sulfate. Lanes 2-4 show the 
purification of the wild type; Lanes 6-11, purified 
mutants.
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Kinetic Comparison of the Two Mutants and Wild Type
The wild type BsPFK and the two mutants, RK252 and 
RA252, follow hyperbolic Michaelis-Menten kinetics with 
respect to both substrates (Figures 14 and 15). Mutation 
to lysine (RK252) increases the Km for Fru 6-P from 0.029 
to 1.16 mM whereas mutation to alanine (RA252) increases 
the Km for Fru 6-P from 0.029 to 41 mM suggesting that the 
decreased affinity of RA252 for Fru 6-P is probably due to 
a removal of a positive charge essential for binding to 
the phosphate group of the substrate. ATP affinity is not 
significantly affected by either mutation (Table 3). The 
assumption of a global conformational transition in the 
enzyme explains these data as well as the change in the 
affinity for PEP which binds at a site far from the Fru 6- 
P binding site (Evans et al., 1981).
The hyperbolic kinetics with respect to Fru 6-P 
concentration is not affected by ATP or NH4+ 
concentrations. Cooperativity is observed in the presence 
of PEP with Hill numbers of 2.2, 2.4, and 1.7 for wild 
type, RK252, and RA252, respectively (Figure 14) at pH 8.2 
and PEP concentrations close to their dissociation 
constants.
ATP inhibition of the wild type and mutants is 
observed at low Fru 6-P concentrations and is reversed by 
GDP or high Fru 6-P concentrations (Figures 5, 15C and 
16). The higher sensitivity of RA252 to ATP inhibition
Figure 14. Dependence of BsPFK activity on Fru 6-P 
concentration in the absence or presence of an effector. 
(A) Wild type, (B) RK252, (C) RA252. •, no effector;o
, 0.5 mM GDP; D , PEP (0.5 mM for wild type, 0.2 mM for 
RK252, 5 uM for RA252); A  , 0.5 mM GDP + the above- 
mentioned PEP concentrations. Standard assays described 
under the Materials and Methods contained 1 mM ATP (A and 
B) and 0.5 mM ATP (C). Relative activities are relative 
to the maximal activity of each enzyme form attained in 
the absence of an effector.
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Figure 15. Dependence of BsPFK activity on ATP 
concentration in the absence or presence of an effector. 
Assays described under the Materials and Methods were done 
at saturating Fru 6-P concentration: • , no effector; o ,
0.5 mM GDP; □ , with indicated concentration of PEP; , 
0.5 mM GDP + indicated concentration of PEP. (A) Wild 
type, [PEP] = 0.5 mM, [Fru 6-P] =1.0 mM. (B) RK252,
[PEP] = 0.2 mM, [Fru 6-P] = 25 mM. (C) RA252, [PEP] =
5.0 uM, [Fru 6-P] = 120 mM. Lineweaver-Burk plots in the 
absence ( • ) or presence (o ) of 0.5 mM GDP are shown in 
the insets.
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Table 3. Effect of Arg-252 mutation on the kinetic parameters 
of BsPFK
Enzyme Form Vmax Km, Fru 6-P Km, ATP Ki, GDP
(umole/min/ (mM) (mM) (mM)
mg )
Wild Type 219 + 4 0.029 + 0.002 0.068 + 0.001 0.49 + 0.04
RK252 4 3 + 1  1.16 + 0.04 0.034 + 0.001 0.32 + 0.05
RA252 8 5 + 9  4 1 + 8  0.086 + 0.007 0.26 + 0.05
Figure 16. ATP inhibition of RA252 activity at low Fru 6- 
P concentration. Initial velocities were measured as 
described under the Materials and Methods using 25 mM Fru 
6-P and the indicated ATP concentrations. The inhibition 
observed in the absence of an effector (D ) or in the 
presence of 0.5 uM PEP (O) was reversed by addition of 
0 .5 mM GDP (•+ ) or 0.5 mM GDP and 0.5 uM PEP ( A ) .
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may be due to poor binding of Fru 6-P and/or higher 
affinity for ATP at the effector site. ATP inhibition at 
low Fru 6-P concentration has been observed in PFK 
preparations from other sources (Simon and Hofer, 1977; 
Kotlarz and Buc, 1981; Fordyce et al., 1982; Marschke and 
Bernlohr, 1982). A negative cooperativity between the 
binding of ATP and Fru 6-P seems to occur in this enzyme. 
For example, the Km of BsPFK for Fru 6-P increases from 
0.029 to 0.072 mM when ATP is increased from 1.0 to 7.0 mM 
(Figure 17). This suggests that the binding of one 
substrate to the active site can influence the binding of 
the second substrate, a relationship not observed in 
EcPFKA (Blangy et al.. 1968).
Mutation of Arg-252 to alanine decreases the Vmax 
from 219 to 85 umole/min-mg. RA252 requires greater than 
100 mM Fru 6-P for saturation (Figure 14C), reflecting the 
complicating effect of high ionic strength rather than 
true saturation. RK252, on the other hand, has a Vmax of 
43 umole/min-mg. The e -amino group of Lys-252 probably 
interacts with Fru 6-P or with an adjacent amino acid 
residue which would affect the spatial orientation of the 
substrate and the catalytic rate of the enzyme. Since the 
mutation of Arg-252 to alanine did not abolish the enzyme 
activity, I surmise that this residue does not participate 
directly in the catalytic process.
Figure 17. Effect of ATP concentration on Fru 6-P 
affinity for the wild type BsPFK. BsPFK activities were 
determined as described under the Materials and Methods 
using either 1 mM (o ) or 7 mM (-f ) ATP and the indicated 
Fru 6-P concentrations.
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Effects of PEP and GDP
PEP is a potent inhibitor of the wild type BsPFK, 
RK252 and RA252. The dissociation constants of PEP at 
saturating concentrations of Fru 6-P and ATP are 0.44,
0.19 and 0.0065 mM, respectively (Figure 18). Affinity 
for PEP increases at high ATP concentrations whereas 
negative cooperativity is observed between PEP and Fru 6-P 
(Table 4). The high sensitivity of RA252 to PEP can be
explained by a major conformational change as a result of
the Arg-252 mutation.
Inhibition by PEP is reversed by GDP (Figure 14). 
However, in the absence of PEP, GDP per se competes with 
ATP (Figure 15). ADP exerts a similar effect (Figure 19). 
The Ki values for GDP are 0.49, 0.32, and 0.26 mM for the 
Wild Type, RK252, and RA252, respectively. These results 
imply that GDP can bind at two separate sites: namely the 
effector and the ATP binding sites. The ATP binding site
of BsPFK seems to be less specific than that of the
EcPFKA. I obtained Km values of 0.068 and 0.156 mM for 
ATP and GTP, respectively for BsPFK, whereas EcPFKA has a 
comparable affinity for ATP (Km = 0.06 mM) but a 7-fold 
less affinity for GTP (Km = 1.2 mM) (Blangy et al., 1968). 
This explains the competitive inhibition of BsPFK by both 
ADP and GDP. On the other hand, ADP, but not GDP, is a 
competitive inhibitor of EcPFKA (Blangy et al., 1968).
Figure 18. Effect of Arg-252 mutation on the dissociation 
constant of PEP. The enzymes were assayed in the presence 
of 1 mM ATP and saturating Fru 6-P concentrations: 1 mM 
Fru 6-P for the wild type ( • ), 50 mM Fru 6-P for RK252 
(o ), and 120 mM Fru 6-P for RA252 ( A  ) . The absolute 
value of the X-intercept is equal to the dissociation 
constant of PEP (Blangy et al., 1968).
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Table 4. Effect of the concentration of Fru 6-P and ATP on the 
PEP dissociation constant of the wild type BsPFK, RK252 and 
RA252 mutants
Enzyme Form [Fru 6-P], (mM) [ATP], (mM) Kpep, (mM )
Wild Type 1 . 0 1 . 0 0 .44 + 0.02
0 . 2 1.0 0. 15 + 0.02
1 .0 0. 1 9.59 +_ 0.02
RK252 50.0 1.0 0 . 19 + 0.05
5.0 1 . 0 0.03 + 0.01
50 . 0 0. 1 0 . 30 + 0 . 04
RA25 2 120.0 1 .0 0.0065 + 0.0008
50.0 1 . 0 0.0047 + 0.0006
120.0 0.1 0.047 + 0.002
Figure 19. Inhibition of wild type BsPFK activity by ADP. 
Activities were measured using 1 mM Fru 6-P, the indicated 
concentrations of ADP and various ATP concentrations: □, 1 
mM ATP; +, 1.58 mM ATP; and O , 3.2 mM ATP.
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Discussion
The data presented in this study support a central 
role for Arg-252 in the substrate binding site through 
maintenance of subunit orientation (Figure 9). Mutation 
of Arg-252 to lysine results in a moderate decrease in the 
affinity of the enzyme for Fru 6-P while substitution with 
alanine which has a smaller, uncharged side chain causes a 
much more drastic fall in affinity (Table 3). The 
observed changes in Km further suggest that Arg-252 plays 
a role in R to T transition based upon comparison with 
previously reported Km changes for EcPFKA during 
transition (0.0125 to 25 mM) (Blangy et al., 1968)). 
Concomitant analysis of PEP binding reveals that the 
dissociation constants for PEP decrease in the two mutants 
studied (Table 4). The more moderate decrease observed in 
the lysine mutant suggests that its long, positively 
charged side chain meets the minimal requirements for 
holding the subunits in the wild-type structure. The 
importance of a single amino acid residue in the 
maintenance of quaternary structure is revealed by the 
dramatic fall in the dissociation constant for PEP seen in 
the alanine mutant. Since PEP affinity is increased in 
the T state (Blangy et al., 1968), results with the 
alanine mutant further support the R to T transition 
model.
CHAPTER V 
MUTATION OF ARG-25, ARG-211 AND ASP-59 
Mutation, Expression and Purification
Arg-25, Arg-211 and Asp-59 have been proposed to be 
involved in the binding of ADP and PEP (Table 1 and Figure 
20). The positively-charged side chain of the first two 
amino acid residues interact with negatively-charged 
phosphate group(s) of the effectors. If Asp-59 interacts 
with the same group, it is probably mediated by Mg2+.
These residues have been mutated to Ala. Asp-59 has also 
been mutated to methionine. I designate Arg-25 ** Ala as 
RA25, Arg-211 -*■ Ala as RA211, Asp-59 -> Ala as DA59 and 
Asp-59 Met as DM59. Figure 21 shows the nucleotide 
sequences for the four mutants. Similar to the wild type, 
these mutants are all stable at 70°C for 15 min and have 
the same relative electrophoretic mobility in SDS-PAGE 
(Figure 13).
Effects of Fru 6-P and ATP Concentration on BsPFK Activity
The wild type BsPFK and the mutants, except RA25, 
follow hyperbolic Michaelis-Menten kinetics with respect 
to Fru 6-P and ATP (Figures 22 and 23) and exhibit the 
same affinity for these substrates. RA25 exhibits the 
same hyperbolic profile with respect to ATP but it shows a 
slight sigmoidicity with respect to Fru 6-P concentration
102
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Figure 20. BsPFK effector site. ADP is bound between two 
subunits shown by the solid and open bonds. (Adapted from 
Evans et al., 1981.)
RRG154
HIS215
THR158
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Figure 21. DNA sequence showing the mutations of Arg-25, 
Arg-211, and Asp-59. In vitro mutation was carried out 
according to Kunkel's protocol (Kunkel, 1985). Sequencing 
was performed by dideoxy chain termination method as 
described under the Materials and Methods. WT, wild type; 
RA25, Arg-25 + Ala; RA211, Arg-211 Ala; DA59, Asp-59 
Ala; DM59, Asp-59 Met.
W T RA25
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Figure 22. Dependence of BsPFK mutant activity on Fru 6-P 
concentration in the absence or presence of an effector. 
All assays contained 1 mM ATP and the indicated Fru 6-P 
concentrations. (A) RA25, (B) RA211, (C) DA59, (D) DM59.
D , no effector; *t, 0.5 mM GDP; 0.5 mM PEP; A , 0.5 mM 
GDP + 0.5 mM PEP.
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Figure 23. Dependence of BsPFK mutant activity on ATP
concentration in the absence or presence of an effector 
All assays contained 1 mM Fru 6-P and the indicated ATP 
concentration. (A) RA25, (B) RA211, (C) DA59, (D) DM59
□ , no effector; +,0.5 mM GDP; 0.5 mM PEP; A, 0.5
GDP + 0.5 mM PEP.
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(Figure 24). Its affinity for Fru 6-P is half of the wild 
type and the other mutants and it has a Hill number of 2.0 
which implies the presence of cooperativity as far as Fru 
6-P binding is concerned.
Effects of PEP and GDP on Mutants and Wild Type Activity
PEP is a potent inhibitor of the wild type BsPFK.
Mutation of Asp-59 to alanine or methionine renders BsPFK 
slightly more sensitive to PEP inhibition (Figure 25).
The dissociation constants of PEP are 0.44, 0.42 and 0.16 
mM for wild type, DA59 and DM59, respectively (Table 5).
GDP and high Fru 6-P concentrations reverse the inhibition 
by PEP (Figure 22).
RA25 and RA211 exhibit 100-fold less sensitivity to 
PEP than does the wild type (Table 5 and Figure 25). No 
sigmoidicity is observed with respect to Fru 6-P in the 
presence of the inhibitor. Addition of GDP does not 
affect the kinetic profile of these two mutants (Figures 
22 and 23).
Discussion
Previous kinetic studies (Chapter III, this 
dissertation) have shown that the wild type BsPFK is 
allosterically different from the major E. coli PFK. The 
former exhibits a hyperbolic curve with respect to Fru 6-P 
whereas the latter shows sigmoidal behavior. Mutation of
Figure 24. Comparison of the effect of Fru 6-P 
concentration on the activity of the wild type BsPFK and 
the four mutants. Activities were measured as described 
under the Materials and Methods using 1 mM ATP and the 
indicated concentrations of Fru 6-P. o, wild type; O, 
RA25; V , RA211; Q , DA59; A , DM59.
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Table 5. Kinetic parameters of the mutants and wild type BsPFK
Enzyme Form Km, Fru 6-P Kpep, (mM)
(mM)
Wild Type 0.029 + 0.002 0.44 + 0.02
RA25 0.06 + 0.01 45 + 9
RA211 0.029 + 0.003 50 + 10
DA59 0.027 + 0.003 0.42 + 0.07
DM59 0.028 + 0.003 0.16 + 0.02
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Figure 25. Effect of PEP concentrations on the activity 
of BsPFK. Activities were measured as described under the 
Materials and Methods in the presence of 1 mM ATP, 1 mM 
Fru 6-P and indicated concentrations of PEP in the absence 
(open marks) or presence (closed marks) of 0.5 mM GDP.
(A) Wild type, with ( • ) and without (o ) GDP; DA59, with 
( ■ ) and without ( □ ) GDP; DM59, with (▲ ) and without 
( A )  GDP. (B) RA25, with (♦) and without (O) GDP;
RA211, with (V ) and without ( V )  GDP.
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Arg-25 to Ala, a residue at the regulatory site, causes a 
dramatic change in the degree of cooperativity between the 
subunits of BsPFK. This mutation probably causes amino 
acid residues at the regulatory site to orient themselves 
in a conformation similar to that they assume in the 
presence of PEP. Addition of PEP to RA25 does not 
increase the cooperativity due to poor binding of the 
inhibitor. Change in cooperativity between subunits has 
also been reported in E. coli aspartate transcarbamoylase 
by mutation of single amino acid residue (Eisenstein et 
al., 1988).
X-Ray structure of BsPFK shows that Arg-25 binds to 
the a- and 8-phosphates of ADP or GDP and Arg-211 binds to 
the a-phosphate and adenine group of ADP or GDP (Figure 
20) (Hellinga and Evans, 1985). The low sensitivity to 
PEP inhibition and the inability of GDP to reverse this 
effect prove unequivocally that Arg-25 and Arg-211 are 
involved in the binding of both modulators. This suggests 
that the positively charged guanidinium moiety of arginine 
interacts with the negatively charged phosphate group (s) 
of ADP, GDP or PEP and a metal ion is not needed in this 
interaction.
Results on PEP and GDP binding of the two Asp-59 
mutants suggest that the side chain of this amino acid 
residue is not directly involved in the binding of these 
modulators. This is consistent with the X-ray structure
of BsPFK which shows that the polypeptide part of Asp-59, 
but not its side chain, binds to the 3-phosphate of ADP or 
GDP (Figure 20) (Hellinga and Evans, 1985). This is 
logical in terms of very poor electrostatic interaction 
between two negatively charged groups (i. e. carboxyl of 
Asp and phosphate of ADP or PEP) unless a metal ion 
bridges them. The 3-fold sensitivity of DM59 to PEP 
inhibition compared to the wild type can not be explained 
in terms of the nature of the side chain. However, it is 
important to note that Asp-59 is replaced by methionine in 
the homologous rabbit muscle PFK and modification of this 
residue does not affect the properties of the eucaryotic 
enzyme (Latshaw et al., 1987).
The above-mentioned mutations define the role of Arg- 
25, Arg-211 and Asp-59 in BsPFK. Other mutations have to 
be conducted to gain more information on the mechanism of 
regulation of BsPFK and the interaction between its 
subunits.
CHAPTER VI
MOLECULAR CLONING AND SEQUENCING OF A PARTIAL HUMAN MUSCLE 
FRUCTOSE 6-PHOSPHATE-1-KINASE GENE
Cloning and Sequencing of HMPFK Gene
Lambda phage plaques containing human DNA inserts 
were screened for the PFK gnes with a nick-translated 
M13mpl8 bacteriophage RF DNA containing the 5' region 
fragment of RMPFK gene (corresponding to the N-terminal 
region of the enzyme) as hybridization probe. Only one 
positive plaque gave a reproducible signal on duplicate 
filters (Figure 26A). This plaque was further purified by 
replating (Figure 26B). DNA from the purified phage clone 
was characterized by digestions with several restriction 
endonucleases followed by nitrocellulose blot 
hybridization with a nick-translated phage RF DNA 
containing the 5' region of RMPFK gene (Figure 27A) or an 
end-labeled oligonucleotide complementary to codons No. 3 
to 9 in the first exon of rabbit PFK gene (Figure 27B) as 
probes. The restriction map is shown in Figure 28. The 
2.8 kb EcoRI/Hindlll fragment was subcloned in M13mpl8 and 
M13mpl9 phage vectors. M13 phage plaques were then 
selected for the PFK insert by their p-galactosidase 
phenotype and by dot blot hybridization. Single-stranded 
phage DNA from these M13 phage clones were purified and 
used as templates for DNA sequence analysis. The primers
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Figure 26. Purification of human PFK gene cloned in 
lambda EMBL4 phage DNA. Human liver DNA was partially 
digested with Mbol endonuclease, size fractionated by 
sucrose centrifugation and ligated into the BamHI site of 
the vector. Phage (at a titer of 300,000 pfu) were seeded 
with NM539 E. coli cells on 10 LB agarose plates (150 mm). 
Nitrocellulose filters in duplicate were lifted from each 
plate and hybridized with nick-translated 5' fragment of 
rabbit PFK gene. A positive plaque shown to have 
reproducible pattern in duplicated filters (A) was 
isolated and further purified by replating (B).
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Figure 27. Nitrocellulose blot hybridization of human PFK 
gene fragments. Purified lambda EMBL4 phage DNA 
containing human PFK genomic insert was digested by EcoRI 
(E), HindiII (H), and SstI (S) endonucleases singly or in 
combination. Fragments produced were separated by 
electrophoresis on an 0 .8% agarose gel, blotted onto 
nitrocellulose filters and hybridized with nick-translated 
M13mpl8 RF DNA containing the 5' region of rabbit PFK gene 
(A) or end-labeled synthetic oligonucleotide corresponding 
to codons No. 3 to 9 of RMPFK (B). The size markers (M) 
are EcoRI and HindiII-digested lambda phage DNA.
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Figure 28. Restriction map of the upstream region of the 
HMPFK gene. The insert at the BamHI site of EMBL4 is 13.7 
kb. The approximate position of the first exon is shown 
by the box. E, EcoRI; H, Hindlll; B, BamHI
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used in these analyses were M13 universal primer and 
synthetic oligonucleotides corresponding to codons 3 to 9 
or complementary to codons 23 to 28 (PFK1 and PFKhl, 
Appendix 6). Total sequence of approximately 400 bp in 
the 5' region of the HMPFK gene has been determined.
Figure 2 9 shows this sequence aligned with the 
corresponding region of RMPFK gene.
Discussion
A partial sequence of the 5' region and exon I of the 
HMPFK gene is shown in Figure 29. Comparison of the 
sequence data with that reported for a HMPFK cDNA 
(Nakajima et al., 1987) shows a perfect match in the first 
exon and the presence of an additional intron extending 
from nt -97 to -9 upstream of the ATG start codon 
(downward arrows in Figure 29). The sequence of the 
splice junction agrees with the consensus sequences 
including CTGAC (nt -31 to -27) as a possible branch point 
(Breathnack and Chambon, 1981). The 5' end of the intron 
has slightly lower homology (67%) with the consensus 
sequence; the same degree of homology exhibited by 8 out 
of 22 introns in the rabbit muscle PFK gene (Lee et al., 
1987) . These comparisons suggest that the region is an 
active intron. The presence of intron in the 5' 
nontranslated region has been reported in actin genes of 
Drosophila (dma2), chicken skeletal muscle, rat skeletal
Figure 29. Alignment of amino acid sequences and DNA 
sequences of human (HMPFK) and rabbit (RMPFK) PFK genes in 
the first exon region. Capital letters are nucleotide in 
the first exon. Flanking regions and introns are printed 
in lower case letters. Boldface letters are positions of 
base substitution and amino acid replacement. Downward 
arrows point to the splice junction. The short sequence 
on top is the leading sequence of the HMPFK cDNA.
Sequences in the nontranslated region identical to the 
HMPFK cDNA are underlined.
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Leading sequence of hmpfk cDNA: gcctgactgagagtggatcATG-
hmpfk ctcattctat tcagtcaact ctcttttccc tgaccttagt ttattcccca
hmpfk aataggttcc aattggggtg ggagggatca gggaggaatt aggaccttag
hmpfk tagtcttggg cttgattaca tgacatttca gcttgtcagt ctacaagggt
hmpfk gtggctttcc tctggaagaa gtccaaagct ctcaggctgc aaagctcaga
hmpfk cttggtatag tqqqaqaqcc 4-tqactqaqqt ggctctagcc agtctaattg
hmpfk
rmpfk
ccgttccttt agctagtggc
-gctagcggc
atcttgattc
accttgacc
ctgctgtgtc 
cagctg tc
ttaactgacc
ctaactgacc
hmpfk
rmpfk
attgtcttaa
atcgtcttgc
attctaqaqt
cttctagagt
qqatc ATG ACC CAT GAA 
ggatc ATG ACC CAT GAA
GAG CAC CAT 
GAG CAC CAT
hmpfk
rmpfk
GCA GCC AAA ACC CTG GGG ATT GGC AAA GCC ATT 
GCA GCC AGA ACC CTG GGG GTC GGC AAG GCC ATC
GCT GTC TTA 
GCG GTG CTC
hmpfk
rmpfk
ACC TCT GGT GGA GAT GCC CAA Ggt aaggaggagg-- 
ACC TCC GGC GGA GAT GCC CAA Ggt aaggaggagg—
135
muscle and rat cytoplasm ( $-actin) (Zakut et al., 1982;
Ordahl and Cooper, 1983). An upstream intron in rat 
collagen II gene has been reported to contain an enhancer 
element which controls the cell-specific expression of the 
gene (Horton et al., 1987); hence it is possible that the 
identified upstream intron in HMPFK gene may have the same 
function.
The comparison presented in Figure 29 reveals strong 
sequence conservation between human and rabbit PFK genes. 
Although only a short (62 bp) sequence upstream of the ATG 
codon of the RMPFK gene is available, this flanking region 
is highly homologous to that of the HMPFK gene. This 
short sequence contains both the 3' splicing junction and 
the branch sequence of an intron. The whole upstream 
intron described for the HMPFK gene may also exist in the 
RMPFK gene based on the 8 9% nucleotide homology in the 
coding region of the two genes.
The first exons of the RMPFK and HMPFK genes are 
identical in length (both 87 bp or 29 amino acids) and 
homologous in sequence. Among the 11 sites of 
substitutions, eight are silent. Three substitutions 
resulted in two highly conservative amino acid 
replacements, a Lys -> Arg at position 9 and an lie -*■ Val 
at position 13. Surprisingly, except for one C -*■ G 
transversion, all other base substitution positions are 
A's and T's in HMPFK gene and G's and C's in the rabbit
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gene.
In the nontranslated region, alignment of the 
homologous sequences shows that in rabbit PFK gene, two 
deletions (one and two bp) bracket a six bp region which 
constitutes a PvuII site in the rabbit gene. A -*■ T 
transversion erases this restriction site in the human 
gene. Eight other base substitutions are identified in 
this nontranslated region; again they are A's and T's in 
the human gene and G's and C's in the rabbit gene. In 
comparing the rest of the human muscle PFK cDNA sequence 
(Nakajima et al., 1987) and the rabbit muscle PFK gene 
(Lee et al., 1987) the data show a significant bias for 
A's and T's in the HMPFK gene and G's and C's in the 
rabbit gene. Of the 256 nucleotide substitutions 
identified, 71% are A's and T's in the human cDNA and C's 
and G's in the rabbit gene. The evolutionary selection 
pressures which cause this bias are not known but it is 
interesting to note that this finding is consistent with a 
survey of 13 rabbit coding sequences which showed that G's 
and C's are strongly favored in the third position of 
degenerate codons (Putney et al., 1983). However, this 
observation does not agree with the comparison of 
sequences of human and rabbit 8 -globin genes where no 
such bias has been detected (Kafatos et al., 1977).
CHAPTER VII
SUMMARY
The results reported in this dissertation show the 
difference in the kinetic behavior of BsPFK and EcPFKA 
which have been previously reported to have similar 
properties. BsPFK exhibits a hyperbolic Michaelis-Menten 
kinetics with respect to Fru 6-P while EcPFKA shows a 
sigmoidal profile.
This dissertation also illustrates that BsPFK is a 
good system to study the relationships between structure 
and function in PFK by site-directed mutagenesis. Kinetic 
data are presented to show that mutation of Arg-252 to Ala 
converts BsPFK to its allosterically inhibited 
conformation (tight or T form). Truncation of Arg-25 and 
Arg-211 to Ala makes the enzyme insensitive to its 
inhibitor phosphoenolpyruvate. Mutation of Asp-59 to 
either Ala or Met seems not to significantly affect the 
regulation of BsPFK. The results obtained in this 
procaryotic enzyme may have relevance in the understanding 
of the homologous but more complex eucaryotic PFK.
In summary, site-directed mutagenesis of putative 
critical amino acid residues is an excellent tool for the 
investigation of enzymological phenomena like R to T 
transition and modulator binding in allosteric enzymes. 
This tool will facilitate-future research on the molecular
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basis of enzyme regulation especially PFK, the key 
regulatory enzyme of the glycolytic pathway.
The last part of this dissertation is an initial 
attempt in the characterization of the 5' nontranslated 
region of the HMPFK gene. An intron upstream of the ATG 
initiation codon has been identified. This probably plays 
an important role in the tissue-specific expression of 
this gene.
CHAPTER VIII 
FUTURE DIRECTIONS
The results presented in this dissertation provide 
the initial set of data for a more complete understanding 
of the relationship of structure and function in BsPFK. 
Prior to subsequent mutations, a thorough comparison in 
the kinetic behavior of the wild type EcPFKA and BsPFK, 
which is not available in the literature, may be 
investigated. The enzymology of EcPFKA has been 
thoroughly studied unlike BsPFK. However, the X-ray 
structure of BsPFK is known but not that of EcPFKA; hence 
literature explains kinetic data of EcPFKA using the known 
structural details in BsPFK. The availability of the 
cloned EcPFKA and BsPFK will facilitate the investigation 
of the differences and similarities in these two 
procaryotic enzymes previously assumed to be similar.
The order of ligand binding (substrates and 
products), anomeric specificity and NH4+-dependent 
mechanism of catalysis may be investigated similar to what 
have been reported in other systems (Simon and Hofer,
1978; Younathan et al., 1981; Abrahams and Younathan,
1971) .
Conclusions presented in this dissertation on Arg-252 
mutations are all based on kinetic data. The R to T 
transition model may be ultimately tested by determining 
the X-ray structure of RA252 and comparing it with the
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known 3-dimensional structure of the wild type.
Further investigation on cooperative interactions may 
be conducted by more mutations at the Fru 6-P binding 
site. Truncation of amino acid residues at this site like 
Asn-12, Thr-156, Arg-162, Arg-243 and His-160 may be 
helpful in the investigation of homotropic cooperativity. 
Similar to Arg-252, these residues have been proposed to 
be involved in Fru 6-P binding and/or subunit interaction.
The existing Arg-252 mutants may be tested for sugar 
specificities. Fru 1-P is a poor substrate of procaryotic 
PFKs. Its rate of phosphorylation may be studied using 
the Arg-252 mutants. Fru 2-P may be tested similarly.
The sigmoidal behavior of RA25 mutant provides an 
insight into the cooperative interaction between subunits. 
Mutations of other amino acid residues at the effector 
site may increase the heterotropic cooperativity.
Simultaneous multiple mutations at this site may convert 
BsPFK to a form with properties similar to EcPFKA, i.e. 
sigmoidal kinetics with respect to Fru 6-P. One 
interesting residue is Gly-55 in BsPFK (Tyr in EcPFKA) 
which may be mutated to Tyr. Tyr-55 in EcPFKA has been 
proposed to bind with ADP (Lau et al., 1987). Moreover, 
the negatively-charged side chain of Asp-59 may be changed 
to Arg. This may enhance the binding of the modulators.
By systematic mutations of all the residues at the 
effector site and by careful classification of the effects
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that these changes may bring about, one might be able to 
discover mutations which interchange the properties of the 
modulators: ADP and GDP may become inhibitors, and PEP an 
activator.
To clearly understand how the effector site 
functions, PEP (a very effective inhibitor), 
phosphoglycolate (less effective inhibitor) and 2- 
phosphoglycerate (similar in structure to PEP but not an 
inhibitor) affinities may be investigated using the 
existing and the future mutants.
Mutants which have been expressed and purified but 
remain to be characterized are RA154, WA17 9 and WF179.
The mutation of the sole Trp residue in BsPFK may be 
important for some fluorometric analyses.
The isolated 5' flanking region of the human muscle 
PFK gene needs further characterization. The TATA box and 
Cap site remain to be located. Identification of possible 
enhancer(s) in this region and isolation of any trans­
acting factor involved in transcription of this gene is a 
very promising project.
ABBREVIATIONS
A - Adenine
ADP - Adenosine diphosphate
AMP - Adenosine monophosphate
ATP - Adenosine triphosphate
bp - Base pair(s)
BSA - Bovine serum albumin
BsPFK - Bacillus stearothermophilus PFK
C - Cytosine
cAMP - 3',5'-cyclic AMP
cDNA - Complementary DNA (transcribed or copied
from mRNA)
C-type PFK - Brain isozyme of PFK
DA59 - Asp-59 to Ala mutant
DM59 - Asp-59 to Met mutant
DMSO - Dimethylsulfoxide
DMT - Dimethyltrityl
DTT - Dithiothreitol
EcPFK - Escherichia coli PFK
EcPFKA - Major EcPFK
EcPFKB - Minor EcPFK
EDTA - Ethylenediaminetetraacetic acid
Fru 1,6-P2 - Fructose 1, 6-bisphosphate
Fru 2,6-P2 - Fructose 2,6-bisphosphate
Fru 6-P - Fructose 6-phosphate
G - Guanine
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GDP - Guanosine diphosphate
Glu 1,6-P2 - Glucose 1,6-bisphosphate 
GTP - Guanosine triphosphate
HEPES - N-2-Hydroxyethyl piperazine-N'-2-ethane
sulfonic acid 
HMPFK - Human muscle PFK
HMpfk - Gene coding for HMPFK
IPTG - Isopropyl-$ -D-thiogalactopyranoside
hr - hour(s)
kb - Kilobase pairs
Km - Michaelis constant
L-type PFK - Liver isozyme of PFK 
mA - milliampere(s)
M-type PFK - Muscle isozyme of PFK 
Man 1,6-P2 - Mannose 1,6-bisphosphate 
min - minute(s)
NAD - Nicotinamide adenine dinucleotide
NADH2 - Nicotinamide adenine dinucleotide (reduced)
nt - nucleotide(s)
OD - Optical density
PAGE - Polyacrylamide gel electrophoresis
PEG - Polyethyleneglycol
PEP - Phosphoenolpyruvate
PFK - 6-Phosphofructo-l-kinase
Pi - Inorganic phosphate
PMSF - Phenylmethylsulfonyl fluoride
RA25 - Arg-25 to Ala mutant
RA252 - Arg-252 to Ala mutant
RF - Replicative form
RK252 - Arg-252 to Lys mutant
RMPFK - Rabbit muscle PFK
RMpfk - Gene coding for RMPFK
SDS - Sodium dodecylsulfate
T - Thymine
TCA - Tricarboxylic acid cycle
TEAB - Triethylamine buffer
TEMED - N, N, N', N'-tetramethylethylenediamine
TLC - Thin layer chromatography
TrisCl - Tris(hydroxymethyl)aminomethane chloride
Vmax - Maximum velocity
X-gal - 5-Bromo-4-chloro-3-indolyl- $ -D-galactoside
Appendix 1
Procedure provided by BRL for transformation of subcloning 
efficiency E . coli DH5a competent cells with some 
modifications:
1. Mix 20 ul competent cells with 1 ul ligation reaction 
by moving pipette through cells while dispensing.
2. Incubate on ice for 30 minutes.
3. Heat shock at 37°C for 20 seconds.
4. Place microfuge tube on ice.
5. Add 0.95 ml of LB.
6 . Shake at 225 rpm for 1 hr at 37°C.
7. Concentrate cells by microcentrifuging for 5 seconds 
and resuspend in 110 ul LB.
8 . Plate 90 ul, 10 ul and 1 ul on LB plates containing 50
ug/ml ampicillin. Add 100 ul LB to the 10 ul and 1 ul
volumes for spreading.
9. Incubate overnight at 37°C.
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Appendix 2
Preparation of DF1020 Competent Cells (Hanahan, 1983)
1. Inoculate 50 ml SOB medium in 500 ml Erlenmeyer flask 
with 5 overnight-grown colonies of DF1020.
2. Incubate at 37°C until the cell density is 6-9 X 107 
cells/ml.
3. Pellet the cells by centrifugation at 750 - 1,000 X g
for 12 - 15 min at 4°C and drain the pelleted cells
thoroughly.
4. Resuspend the cells in 16 ml frozen storage buffer 
(FSB, preparation described below) by vortexing 
moderately. Incubate on ice for 10-15 min.
5. Pellet the cells as before, and drain thoroughly.
6 . Resuspend the cells in 4 ml FSB.
7. Squirt 145 ul DMSO into the center of the cell
suspension and immediately swirl the tube for 5 - 1 0  sec.
Incubate on ice for 5 min.
8 . Add 145 ul DMSO as before and incubate on ice for 10-
15 min.
9. Pipette 200 ul aliquots into chilled 1.5 ml 
microcentrifuge tube and flash freeze in a dry ice/ethanol 
bath for several min.
10. Store at -70°C.
Preparation of frozen storage buffer (FSB):
Compound Amount/liter Final Concentration
KC1 7.4 g 100 mM
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MnCl2.4H20 8.9 g 45 mM
CaCl2.2H20 1.5 g 10 mM
HACoC13 0.8 g 3 mM
Potassium acetate 10 ml of 1 M
stock (pH 7.5) 10 mM
Glycerol (pH 6.2) 100 g 10 % (w/v)
Adjust a 1 M solution of potassium acetate to pH 7.5 using
KOH, then sterilize by filtration through a 0.22 urn
membrane and store frozen. Prepare a 10 mM potassium
acetate, 10 % glycerol solution using this stock and
purest available water. Add the salts as solids, and
adjust the pH to 6.4 using 0.1 N HC1. Do not adjust the
pH upward with base. (The pH will drift for 1-2 days
before settling at 6 .1-6.2.) Sterilize the solution by
filtration through a pre-rinsed 0.22 urn filter, and store
at 4°C.
Preparation of SOB Medium:
Per liter:
Bacto-tryptone 20 g
Yeast extract 5 g
NaCl 0.5 g
Adjust to pH 7.5 with potassium hydroxide and 
sterilize by autoclaving. Just before use, add 20 ml of 
1 M MgS04, sterilized separately by autoclaving.
Appendix 3
Procedure provided by BRL for transformation of E . coli 
DH5aF' competent cells with minor modifications.
1. Mix 30 ul competent cells with 1 ul diluted ligation 
reaction into chilled Eppendorf tube by moving pipette 
through cells while dispensing.
2. Incubate on ice for 30 min.
3. Heat shock for 45 sec in a 42°C water bath (do not 
shake).
4. Plate tube on ice for 2 min.
5. Add competent cells to 3.0 ml YT top agar containing 
100 ul lawn cells, 50 ul 2 % X-gal and 10 ul 100 mM 
isopropyl-B-D-thiogalactopyranoside (IPTG). X-gal and 
IPTG are added just before use.
6 . Pour on YT plate and spread gently.
7. Allow top agar to solidify at room temperature and 
incubate the plates overnight at 37°C.
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Appendix 4
DNA Sequencing Using Sequenase Kit (USBC)
This is a protocol provided by the supplier with minor 
modifications.
A. Sequencing Reactions and Gel Electrophoresis
(I used color coded tubes, i.e. A:blue, C:green,
Grwhite, T:yellow.)
1. In an Eppendorf tube combine 1 ul primer (2.5 ng/ul),
2 ul sequencing buffer and 7 ul template DNA 
(approximately 1 ug).
2. Warm the capped tube to 65°C for 30 min.
3. Place the tube at room temperature on the bench for 10 
min.
4. Place 2.5 ul of the ddGTP termination mix in a tube 
labeled G. With a fresh tip for each, fill A, T and C 
tubes with 2.5 ul of the ddATP, ddTTP and ddCTP 
termination mixes respectively. Cap the tubes and prewarm 
at 37°C for 1 min.
5. To the annealing mix (step 3) add 1 ul of 0.1 M DTT, 2 
ul of 5-fold diluted labeling mix, 0.5 ul [a-35s ]thio-dATP 
(10 uCi/ul, 10 uM) and 2 ul of Sequenase diluted 1:8 in 
ice-cold TE. Mix thoroughly with a pipet and incubate at 
room temperature for 5-10 min.
6 . When the labeling incubation is complete, remove and 
transfer 3.5 ul to each labeled tube in step 4. Mix 
content of each tube, centrifuge and continue incubation
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at 37°C for at least 5 min.
7. Add 4 ul stop solution to each tube.
8 . Heat the samples to 75-80°C for 2 min and load 
immediately on the gel 2-3 ul in each lane. Use shark- 
tooth comb from BRL.
9. The gel should be pre-run with a power of not more 
than 60 watts for 15 min before loading the samples. Run 
the gel with samples using the same condition until the 
fast moving dye reaches the bottom of the gel.
10. After running, soak the gel in 10 % acetic acid/10 % 
methanol for 30 min and transfer onto a 3 MM Whatman
paper. Dry at 80°C under vacuum for 1 hr.
11. Expose the gel at room temperature with a direct 
contact between the Kodak film and the gel for 18 hrs or 
longer.
B. Preparation of the Gel
1. Prepare 40 % acrylamide solution by mixing 38.0 g 
acrylamide, 2.0 g N', N'-methylenebisacrylamide and dH20 in 
a total volume of 100 ml. Stir gently with 2.0 g mixed 
bed resin (Amberlite MB1) for at least 30 min. Filter 
through a Buchner funnel. The filtrate may be stored in a 
brown bottle at 4°C.
2. Prepare 6 % gel mix in 0.5X TBE by mixing 37.5 ml 40 %
acrylamide, 12.5 ml 10X TBE and 115 g urea. Make the
total volume to 250 ml with H20. Pass through 0.45 urn 
membrane. Keep at 4°C in a brown bottle.
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3. Degas 75 ml 6 % gel mix/O.5X TBE for 15 min at room 
temperature. Transfer on a beaker and while stirring add 
150 ul of 25 % ammonium persulfate and 30 ul TEMED.
4. Pour the gel mix between two glass plates using 0.2 
or 0.4 mm thick spacers. The shorter glass plate should 
be siliconized.
5. Let it polymerize for 2 hrs.
C. Contents of USBC Sequenase Kit
1. 5X sequenase buffer (200 mM Tris-Cl, pH 7.5, 50 mM 
MgCl2, 250 mM NaCl) .
2. Control DNA M13mpl8 (0.2 ug/ul)
3. Universal primer (0.5 pmol/ul)
4. 0.1 M DTT
5. 5X dGTP labeling mix (7.5 uM dGTP, 7.5 uM dCTP, 7.5 uM 
dTTP)
6 . 5X dITP Labeling mix (15 uM dITP, 7.5 uM dCTP, 7.5 uM 
dTTP)
7. ddG termination mix for dGTP (80 uM dGTP, 80 uM dATP,
80 uM dCTP, 80 uM dTTP, 8 uM ddGTP)
8 . ddA termination mix for dGTP (same as in # 7 but with 
8 uM ddATP instead of ddGTP)
9. ddT termination mix for dGTP (as # 7 but with 8 uM 
ddTTP instead of ddGTP)
10. ddC termination mix for dGTP (as # 7 but with 8 uM 
ddCTP instead of ddGTP)
11. ddG termination mix for dITP (160 uM dITP, 80 uM dATP,
80 uM dCTP, 80 uM dTTP, 1.6 uM ddGTP)
12. ddA termination mix for dITP (as in # 11 with 8 uM
ddATP instead of ddGTP)
13. ddT termination mix for dITP (as in # 11 with 8 uM 
ddTTP instead of ddGTP)
14. ddC termination mix for dITP (as in # 11 with 8 uM 
ddCTP instead of ddGTP)
15. Sequenase enzyme
16. Stop solution (95 % Formamide, 20 mM EDTA, 0.05%
Bromophenol Blue, 0.05% Xylene Cyanol FF).
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Appendix 5
Plaque Hybridization and Screening With 
Tetramethylammonium Chloride Wash (S. Lee, personal 
communication)
1. Chill plates with 100-200 plaques for 10-30 min at 
4°C.
2. Lay flat a dry nitrocellulose filter onto the agar and 
let the phage be adsorbed for 5 min.
3. Orient the filter by stabbing an inked needle through 
the filter.
4. Peel carefully the filter off; avoid pulling agar off.
5. Air dry the filter for 5 min on a sheet of 3 MM
Whatman filter paper.
6 . Make duplicate filter by repeating steps 2-5 with a 
fresh nitrocellulose filter.
7. Wet a sheet of Whatman paper with 0.5 N NaOH/1.5 M 
NaCl draining off the excess liquid by rolling a glass 
rod.
8 . Place the nitrocellulose filters onto the paper, 
plaques up, for 5 min.
9. Transfer with forceps to a sheet of dry Whatman paper 
and let them air dry for 2-3 min.
10. Repeat steps 8 and 9.
11. Place filters onto a sheet of Whatman paper soaked
with 1 M Tris-Cl (pH 8.0) for 5 min.
12. Remove the filters and air dry for 2-3 min.
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13. Repeat steps 11-12.
14. Place filters onto a sheet of Whatman soaked with 1 M 
Tris-Cl (pH 8.0)/l.5 M NaCl for 5 min.
15. Transfer the nitrocellulose filters into 100 ml 6X SSC 
for 2 min.
16. Remove and air dry for 10 min.
17. Bake the filters at 80°C under vacuum for 1 hr.
18. Place the filters into clean petri dish, plaques up, 
containing prehybridization solution (6X SSC, 10X 
Denhardt's solution, 0.1% SDS) enough to cover the 
filters.
19. Cover and incubate at 37°C for 1 hr with gentle 
shaking.
20. Replace prehybridization solution with hybridization 
solution (6X SSC, 10X Denhardt's solution, 106 - 107 cpm 
probe).
21. Incubate at room temperature overnight with gentle 
shaking.
22. Transfer the filters into 100 ml 6X SSC and swirl for 
1 min at room temperature.
23. Replace 6X SSC with a fresh solution and swirl for 5 
min.
24. Repeat washing until the Geiger counter does not 
detect counts in the wash.
25. Briefly blot onto 3 MM Whatman paper then wrap filters 
in Saran Wrap. Do not let the filters to air dry.
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26. Autoradiograph for 3 hrs with intensifying screen at 
-70°C.
27. Wash the filters at higher temperature to select the 
mutant. Wash in 3 M tetramethylammonium chloride 
((Me)4NCl) at room temperature for 2-3 min.
29. Transfer in 100 ml 3 M (Me)4NCl preheated at the 
desired washing temperature. (Approximate washing 
temperature for 16-mer: 49-50°C; for 25-mer, 64-65°C.)
Wash 10-15 min in a shaker water bath.
30. Remove the filters and check the signal with a Geiger
counter. If the signal is reasonably high, increase the
washing temperature by 2°C and wash them again.
31. Blot dry the filters, cover with Saran Wrap and 
autoradiograph with intensifying screen at -70°C. The 
duration of exposure depends on the intensity of the 
count.
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Appendix 6
Synthetic oligonucleotides used as primers for in vitro 
mutation and DNA sequencing.
Code Sequence (5' - 3') Start Position* Strand** Remarks
(nt)
BsPFK2 GCGGAACACAACAGCG -103 com seq'ng primer
BSPFK3 CGGGTTTGACACGGCGC 411 cod seq'ng primer
BSPFK4 GGCGACCGTTCGGCCCG 1155 com seq'ng primer
BSPRI5 ATCCCCGACATCGCCG 162 com seq'ng primer
BsPRI6 CGACGCAGCGCCCGCC 838 com seq'ng primer
BsPRI7 CGCGCTCATGGCCGC 620 com seq'ng primer
BsPRI8 GATGACGACCAGCCC 286 com seq'ng primer
BsPRI9 GCGACGTCGCCGTGTCG 461 com seq'ng primer
BsPRlO GGCGTCGACTTCGGC 679 cod seq'ng primer
BsPRI1 GTATGAGGTCGGACG -45 cod seq'ng primer
BsPR12 CGGCCCGCTGTCCGG 209 cod seq'ng primer
Bs252M CCCGCCGGCCTGCACG 747 com make Arg-252 
to Ala mutant
Bs252B CGACCCGCCTTTCTGCACGTGG 744 com make Arg-252 
to Lys mutant
Bs025M CGCTTTGGCGACAACCG 65 com make Arg-25 
to Ala mutant
Bs059A GGATAATCATCCCGAC 169 com make Asp-59 
to Met mutant
Bs059B GGATAATGGCCCCGAC 169 com make Asp-59 
to Ala mutant
Bs211 GTTTTTTGCCGGCCTCATGG 624 com make Arg-211 
to Ala mutant
PFK1 GGCTGCATGGTGCTCTTCATG 7 com HMPFK seq'ng 
primer
PFKn ATGACCCATGAAGAGCACCA 1 cod HMPFK seq'ng 
primer
PFKhl ACCTTGGGCATCTCCACC 70 com HMPFK seq'ng 
primer
Ml3 primer GTAAAACGACGGCCAGT Univ. seq'ng
primer
Starting from first G in initiation codon in BsPFK gene, 
and A in initiation codon in HMPFK gene 
cod: coding; com: complementary
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Appendix 7
Denaturing Gel Electrophoresis (Smith, 1987)
1. Assemble the BIO-RAD gel electrophoresis apparatus 
using 0.75 mm X 14 cm X 14 cm glass plates.
2. Prepare the separating gel solution by mixing 6.0 ml 
of 30 % acrylamide/0.8 % bisacrylamide, 3.75 ml of 4X 
Tris-Cl/SDS (pH 8 .8), and 5.25 ml H20 (see reagents 
below). Degas in a 25-ml sidearm flask for 10-15 min.
3. Add 0.05 ml of 10 % ammonium persulfate and 0.01 ml 
TEMED and gently swirl to mix.
4. Transfer immediately the separating gel solution to 
the center of the sandwich glass plates along an edge of 
one of the spacers until the height of the solution about 
11 cm.
5. Using a Pasteur pipet, slowly cover the top of the gel 
with 1 cm thick of isobutyl alcohol.
6 . After 1 hr at room temperature pour off completely the 
layer of isobutyl alcohol.
7. Prepare the stacking gel solution by adding 0.65 ml of 
30 % acrylamide/0.8% bisacrylamide, 1.25 ml of 4X Tris- 
Cl/SDS (pH 6 .8) and 3.05 ml H20 to a 25-ml sidearm flask.
Degas for 5-10 min. Add 25 ul of 10 % ammonium persulfate 
and 5 ul TEMED and gently swirl to mix.
8. Pour the stacking gel solution on top of the 
polymerized separating gel.
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9. Insert a Teflon comb into the layer of stacking gel 
solution without trapping air bubbles in the tooth edges 
of the comb.
10. Allow to polymerize at room temperature for 1 hr„
11. Dilute an aliquot of the protein to be analyzed at 
least 1:2 (vol/vol) with 2X SDS/sample buffer and boil for 
5 min at 100°C.
12. Carefully remove the Teflon comb and fill the wells 
with IX SDS/electrophoresis buffer.
13. Pour 2 liters of IX SDS/electrophoresis buffer into 
the lower buffer chamber and place the gel in the 
electrophoresis apparatus.
14. Fill partially the upper buffer chamber with 300 ml of 
IX SDS/electrophoresis buffer so that the sample wells of 
the stacking gel are filled with buffer.
15. Load the samples and carefully fill the remainder of 
the upper chamber with an additional IX 
SDS/electrophoresis buffer.
16. Connect the power supply to the cell and run at 10 mA 
at constant current until the tracking dye enters the 
separating gel then increase the current to 15 mA.
17. After the bromophenol blue dye has reached the bottom 
of the separating gel, disconnect the power supply.
18. Fix the gel in 25 % methanol/10 % acetic acid for 30 
min.
19. Stain with Coomassie Brilliant Blue for at least 2
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hrs.
20. Destain with 10 % methanol/10 % acetic acid.
Reagents:
30 % acrylamide/0.8 % bisacrylamide
acrylamide 30 g
N',N-methylene-bisacrylamide 0.8 g
H20 to 100 ml
Filter through a 0.45 urn membrane and store at 
4°C in brown bottle.
4X Tris-Cl/SDS, pH 6.8 (0.5 M Tris-Cl, 0.4% SDS)
Tris base 6.05 g
SDS 0.4 g
H20 50 ml
Adjust to pH 6.8 with 1 N HC1 and add more H20
to 100 ml total volume. Filter through 0.45 urn
membrane and store at 4°C.
4X Tris-Cl/SDS, pH 8.8 (1.5 M Tris-Cl, 0.4% SDS)
Tris base 91 g
SDS 2 g
H20 400 ml
Adjust to pH 8.8 with 1 N HC1. Add H20 to 500 
ml total volume. Filter the solution through 
a 0.45 urn membrane and store at 4°C.
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2X SDS/sample buffer
To 40 ml water add:
Tris base 1 . 52 g
glycerol 20 ml
SDS 2 g
2-mercaptoethanol 2 ml
Bromophenol Blue 1 mg
Adjust to pH 6.8 and complete the ■
100 ml with H20. Filter through 0.45 urn
membrane and store at 4°C.
5X SDS/Electrophoresis buffer
Tris base 15.1 g
glycine 72.0 g
SDS 5.0 g
H20 to 1000 ml 
Staining solution
Coomassie Brilliant Blue R-250 2.5 g
Acetic acid 42 ml
Methanol 454 ml
H20 454 ml
Mix for 1 hr and filter.
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